Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Phase: PHASE2
Conditions: Depressive Disorder, Major
Sponsor: Imperial College London

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
1
F5 QIDS 
 
 
 
 
PROTOCOL VERSION 7 
REC: 17/LO/0389 
Imperial JRCO and sponsor: 17HH3790 
EudraCT: 2017-000219-18 
 
Project Title: Psilocybin vs escitalopram for major depressive disorder: comparative 
mechanisms 
Short title:  PSILODEP-RCT   
 
Chief  Investigator:  
Prof David Nutt 
Co-Investigators: 
Dr Robin Carhart-Harris 
Dr Ros Watts 
Ms Bruna Giribaldi 
Prof Val Curran 
Dr David Erritzoe 
 
Main study centres 
Neuropsychopharmacology Unit 
Centre for Psychiatry, Division of Brain Sciences, Imperial College London 
Burlington Danes Building, Du Cane Rd,  
London, W12 0NN 
 
NIHR/Wellcome Trust Imperial Clinical Research Facility (CRF) 
Hammersmith Hospital, London, W12 0HS 
020 3313 8073  
 
Invicro (previously called IMANOVA) 
Burlington Danes Building 
Imperial College London 
Hammersmith Hospital 
Du Cane Road, London, W12 0NN.       Tel: 020 8008 6000  
 
Centre for Neuropsychopharmacology 
Division of Brain Sciences  
Burlington Danes Building, Du Cane Rd,  
London 
W12 0NN 
Tel: 02075946550  

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
2
Study sponsors:  
Imperial College London 
Financial support:    Mosley Foundation, MRC 
Indemnity:  
 
Imperial College London 
 
Contents 
 
1. Aim of study 
1.1. Basic study design & hypotheses 
 
      
1.2. Background of study  
2. Project Outline - Main study design 
2.1. Dose 
2.1.1. Psilocybin 
2.1.2. Escitalopram 
2.2. Data Collection 
2.2.1 Outcome measures 
2.2.2 Automated prompts for data completion and participant duties 
2.3. Recruitment 
2.3.1. Entry criteria 
2.3.2. Drug interactions 
2.3.3. Recruitment strategy 
2.4. Ethical considerations 
2.4.1. Managing risks related to withdrawal from antidepressants 
2.4.2. Managing risks related to psychedelic treatment 
2.5. Procedures  
2.6. Visits  
2.7. Psychological outcome measures                                                    
2.8. Scanning outcome measures                                                           
   3. Basic safety and scientific background                                              
   4. Study design                                                                                           
4.1. Primary outcomes  
 
4.1.1. Primary fMRI outcome measures and endpoint                     
 
4.1.2. Primary efficacy outcome measures and endpoint              
4.2. Volunteers                                                                                           
4.2.1. Sample size                                                                                      
4.2.2. Recruitment of volunteers                                                             
4.2.3. Screening procedure: Initial screening visit                             
4.2.4. Withdrawal criteria 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
3
5. Regulatory Issues and informed consent                                      
5.1. Ethical Approval                                                                                    
5.2. Consent                                                                                                   
5.3. Confidentiality                                                                                      
5.4. Audits and Inspections                                                                         
5.5. Monitoring                                                                                               
6. Patient recruitment strategy                                                                  
7. Drug specific ethical and safety considerations                                 
7.1. Psilocybin safety                                                                                
7.2. Escitalopram safety  
 
 
7.2.1 Side-effects and SmPC Cautions 
7.2.2 Pregnancy, Breastfeeding and Contraception 
7.3. Suicide and persistent adverse events                                              
7.4. Definitions and reporting of Adverse Events & Reactions                    
7.5. Reporting Procedures                                                                             
8. Standard Operating Procedure (SOP)                                                  
9. Purchasing and storing drug                                                                                     
10. Analysis                                                                                                                         
11. Dosing procedure and patient management                                                             
12. Randomisation                                                                                                          
13. Breaking of blind 
14. Significant other assessment process 
 
 
1. Aim of study 
The aim of this study is to compare the mechanisms, tolerability and efficacy of two high 
doses of psilocybin versus a 6 week course of a leading antidepressant medication, 
escitalopram, in major depressive disorder (MDD). This will be a 2-arm, active comparator, 
double-blind randomised control trial in a total of 60 completing volunteers (‘completing’ 
measured by primary outcome measure).  
 
1.1. Basic study design 
The main experimental condition (condition 1) in this study will involve two high doses of 
25mg psilocybin (per os, p.o.), 3 weeks apart. The first dose will be followed by 6 weeks of 
daily (inert) placebo capsule ingestion (condition 1, fig. 1). The control condition (condition 
2) will involve two dosing sessions, also 3 weeks apart, with a presumed inactive dose of 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
4
psilocybin (1mg p.o.). The first dose will be followed by 6-weeks of daily escitalopram 
capsule ingestion (fig. 1).  
 
Thus, there will be a dedicated on-site dosing day for both conditions (named here ‘initial 
dosing session’) followed by 6 weeks of daily capsule ingestion at home and a second 
dosing session 3 weeks after the first. The primary endpoint for assessing efficacy is 6 
weeks after the initial dosing session, when the blind will be broken at the final study visit. 
Unblinded follow-up will occur for a further 6 months to assess safety and any potential 
enduring effects.   
 
The main purpose of this design is to test the hypothesis that two doses of psilocybin, a 
design similar to what may be done in future therapy, will show a superior efficacy to 
escitalopram and crucially, a different mechanism of action. Secondarily, we predict that 
conditions 1 and 2 will show comparable efficacy at 6 weeks but with a different side-effect 
profile, e.g. we predict that changes in sexual dysfunction will be different across conditions 
and that psilocybin will act more rapidly to alleviate depressive symptoms.  
 
Regarding the primary outcome, we will use functional magnetic resonance imaging (fMRI) 
at baseline and six weeks after the initial dosing session to identify how brain activity 
changes before and after two doses of 25mg psilocybin vs 6 weeks of daily escitalopram.  
 
We predict that fMRI measured amygdala blood oxygen level dependent (BOLD) responses 
to emotional faces after-versus-before treatment will be greater in condition 1 (psilocybin) 
than in condition 2 (escitalopram).  
 
This trial promises to significantly advance our knowledge of the safety, efficacy and 
mechanism of action of psilocybin for MDD by comparing it with a major conventional 
treatment for depression. The comparison with escitalopram adds an important component 
to this trial which may ultimately lead to the development of psilocybin as an alternative 
treatment option for patients with MDD.  
 
1.1 Background of the study 
This study is designed to test the efficacy of psilocybin as a treatment for major depression. 
The burden of depression is severe and increasing. Preventing relapse is a major challenge 
in depression; first line medications and psychotherapy can decrease symptom severity but 
large numbers of patients fail to respond and/or relapse when these are discontinued. 
Psilocybin is a naturally occurring compound that is structurally similar to the endogenous 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
5
neurotransmitter serotonin. Psilocybin had a brief history of use in psychotherapy in the 1960s 
but this was cut short before its efficacy could be properly assessed. In recent years, a growing 
number of studies, including several of our own, have shown that psilocybin can be safely 
administered to human subjects and there are now consistent reports of persistent 
improvements in depressive symptoms in depressed patients and other patient groups after 
just one or two exposures to psilocybin [1; 2; 3; 4; 5]. Our recent open-label feasibility study 
[1] has provided further preliminary support for the safety and efficacy of psilocybin for 
treatment-resistant depression, however the data remains inconclusive because of the lack of 
a control condition. It remains possible that psychological expectations and/or the concomitant 
psychological support the patients received played a significant role in determining outcomes. 
It is now important therefore that psilocybin be tested against an appropriate control condition 
and this is what we propose here.  
 
2. Project outline 
2. Main study design 
This will be a two-arm, active comparator, double-blind, randomized controlled, between-
subjects, design in up to 60 completing patients meeting DSM-IV criteria for major depression 
of a moderate to severe degree (17+ on the 21-item Hamilton Depression Rating Scale, HAM-
D). The patients will be randomly allocated to two groups. Groups will receive either: 1) two 
on-site dosing sessions with 25mg p.o. psilocybin, 3 weeks apart, the first dosing session 
being followed by 6 weeks of daily inert placebo ingestion, 2) two dosing sessions with 1mg 
psilocybin (to our knowledge, sub-psychoactive), 3 weeks apart, the first dosing session being 
followed by 6 weeks of daily escitalopram (10 mg for the first 3 weeks then increasing to 20 
mg for 3 weeks, in line with prescribing guidelines [79] and similar to previous literature [98]). 
See Figure 1 for details.  
Condition one is the main experimental condition and condition 2 is a control condition. 
Condition 2 involves 6-weeks of treatment with a gold-standard antidepressant, escitalopram, 
adding an important comparative efficacy component to this trial. Both groups will receive 
equal preparation and follow-up before and after the dosing session. The blind is broken after 
6 weeks, after which normal treatment ensues.  
 
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
6
 
Figure 1. Basic design. Active components are highlighted in red. Please note, the psilocybin 
‘dosing sessions’ are variously called ‘dosing days’ in what follows  
 
2.1. Dose 
2.1.1. Psilocybin 
Patients in condition 1 will receive two doses of 25mg, 3 weeks apart from each other. In our 
recent open label feasibility study, this dose was well tolerated by all of the patients; no serious 
or unexpected adverse events occurred, and the mean patient rating of intensity of drug effects 
3 weeks 
Dosing Day 1 
Baseline: Scan 1 
°1 fMRI outcome = amygdala BOLD to faces) 
°1 efficacy outcome = QIDS 
 
3 weeks 
3 weeks 
placebo 
(1 capsule 
per day) 
3 weeks 
escitalopram 
(1 capsule 
per day – 
10mg) 
Dosing Day 2 
2nd dosing session 
25mg psilocybin (p.o.) 
2nd dosing session 
1mg psilocybin (p.o.) 
‘placebo’ 
Blind broken 6 weeks post doing day 1 (°1 endpoint + 
scan 2) - QIDS & fMRI re-assessed 
3 weeks 
placebo 
(2 capsules 
per day) 
3 weeks 
escitalopram 
(2 capsules 
per day – 
20mg) 
+ check-
up phone 
call 1-
week 
post-DD1 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
7
was 7.5 (+2.5) out of 10, which was what we had planned to achieve. Based on these 
observations we feel confident that this dose maximises the potential for therapeutic benefit, 
whilst minimising the risk of acute adverse events. This view has been further supported by 
our conversations with other researchers working with psilocybin, such as those at Johns 
Hopkins University.  
 
Regarding the control group, 1mg psilocybin has been chosen because evidence indicates it 
is pharmacologically ‘inert’ and yet capable of serving as an effective placebo [4], producing 
effects via expectancy alone, to a similar degree as a non-active placebo. Positive expectation 
is the major psychological factor underlying the ‘placebo’ effect, so the merit of using psilocybin 
in both conditions is that study staff and patients can be briefed to expect psilocybin in all 
conditions. Patients and therapy staff will be encouraged to expect and prepare for up to 25mg 
of psilocybin; thus, standardizing preparation and expectations prior to the dosing session. 
 
2.1.2. Escitalopram 
Escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) that was licensed in the 
US in 2002 as an approved treatment for major depressive disorder. It has since been 
prescribed to millions of people worldwide, becoming a gold-standard medication for 
depression. Meta-analyses have indicated that escitalopram is one of the best performing 
SSRIs in terms of tolerability and efficacy [77] and it is one of the most selective SSRIs [78].  
Patients in condition 2 who receive an inactive dose of psilocybin (1mg) during the first dosing 
day, will subsequently receive 6 weeks of daily escitalopram. For the first 3 weeks they will 
receive 10mg-daily (1 capsule per day). After 3 weeks they will have a second 1mg psilocybin 
dosing day (without interrupting the daily escitalopram dosing schedule). After this, they will 
subsequently take 20mg of escitalopram daily (2 capsules per day) for three further weeks. 
The dose of 20mg is the recommended maximum dose for this commonly prescribed primary 
treatment for depression, and thus we would expect the patient’s symptoms of depression to 
decrease. It would be expected that patients starting a course of SSRIs would report some 
improvements in depressive symptoms after even this relatively brief treatment period of 6 
weeks  [80, 81]. 
The dose of escitalopram can be lowered to 10mg from 20mg if patients appear not to be 
tolerating 20mg and ask to lower the dose or withdraw from the trial. This would be simple to 
implement as we would just instruct patients to take 1 capsule daily instead of 2. If, when the 
blind is broken at the 6 week endpoint, it transpires that the patient was actually in condition 
1 and not in fact in the escitalopram condition, this would be logged.  

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
8
We will be monitoring patients’ response to escitalopram via weekly self-report measures, and 
measures of side effects. FDA guidelines report the following possible side-effects with 
escitalopram: headaches, dizziness, nausea, insomnia, dry mouth, impotence, decreased 
appetite, weight gain, vomiting, vivid dreams and a tingling sensation in arms, hands, feet and 
legs [79]. Insomnia and diarrhea are the most common side-effects, affecting 15% of 
individuals at 20mg [79].  
When the blind is broken at the end of the 6-week course, the study psychiatrist will conduct 
individual consultations with patients in condition 2 to discuss whether they would like to 
continue with escitalopram or return to treatment as usual after controlled withdrawal. The 
patient’s GP/psychiatrist will be included in treatment planning/medication withdrawal. 
Patients in condition 1 will receive daily placebo (inert) instead of escitalopram over the same 
6-week period following the psilocybin dose (fig. 1). The study psychiatrist will also advise 
patients in condition 1 about treatment options after the trial.  
2.2 Data Collection 
2.2.1 Outcome Measures 
The primary efficacy outcome measure will be the Quick Inventory of Depressive Symptoms 
(QIDS) and changes from baseline to 6-weeks after the psilocybin dosing session. The QIDS 
measures internal states including most of the diagnostic criteria for depression and is 
sensitive to treatment effects [6].  
The 16-item QIDS will be collected weekly from the moment of enrolment up to 6 weeks after 
dosing [12]. It will also be done one day before dosing and one day after dosing (using a 
version of this scale tailored to daily use [82]). After 6 weeks, measures will be collected 
monthly, up to 6 months post-dosing. Secondary outcomes include (but are not limited to): 
additional patient (BDI) and clinician (HAM-D) depression rating scales, well-being 
(WEMWBS), anxiety (STAI), optimism (LOT-R), personality (BIG-5) and others, plus all 
imaging outcomes (e.g. anatomical measures, including: morphometry, cortical thickness and 
tractography; functional measures, including: CBF, BOLD RSFC, signal variance and 
entropy/complexity, and activations to emotional faces). After the 6-week post dosing day 
primary end-point, subsequent follow-up will be done remotely with the exception of a 
structured interview at 1 month and 6 months.  
 
2.2.2 Automated prompts for data completion and participant duties 
The Psychedelic Survey platform (psychedelicsurvey.com) is an external software that was 
created for a recent cohort study conducted by our group (results still unpublished). It was 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
9
used to automate reminder emails to a large number of participants over the course of a few 
months. These emails linked participants to questionnaires contained within the separate 
Survey Gizmo platform, where we stored our data. This was found to be an efficient way to 
optimise collection and safe storage of questionnaire data, so this procedure will be repeated 
for this trial. Using these platforms is an effort to minimise the chance of human error and 
ensure the large volumes of data are collected correctly over the course of the trial.  
For this study, the Psychedelic Survey platform will be programmed to send automatic patient 
reminders, including:  
1. Reminding patients to take escitalopram/placebo every morning, promoting 
compliance 
2. Reminding patients to complete their weekly/monthly QIDS questionnaires. This 
reminder will have a link to the Survey Gizmo platform, where patients will have an 
individual login and can complete the questionnaires online. 
3. Reminding patients of any extra questionnaires to be completed 
4. Reminding patients of onsite meetings 
Reminders will be sent by both text message and email at specific times programmed by the 
study researchers. A limited number of study staff will be able to login to the Psychedelic 
Survey to amend or update patient reminders. 
 
The Psychedelic Survey platform will only have access to patient email addresses and phone 
numbers, no other personal/medical data. This data is considered personal but not sensitive, 
so this project will be in accordance with Schedules I and II of the Data Protection Act [94]. 
Patient consent will be obtained and will not be necessary for inclusion in the study (see patient 
consent form). In accordance with the Data Protection Act [94], this personal data will only be 
used for the purposes of sending reminders and will be deleted after the study is over. More 
information is available on the Psychedelic Survey’s Privacy Policy (attached as an appendix). 
 
Questionnaire data will be stored within the Survey Gizmo platform and not the Psychedelic 
Survey platform. This has been done in previous studies by our group [95 and unpublished 
cohort study which launched the Psychedelic Survey platform]. Only study staff will have 
access to this information and both staff and patients will have individual logins for the website. 
The Research Data Manager for this study (Ms Bruna Giribaldi) will keep track of incoming 
data and patient reminders via these two platforms throughout the clinical trial period.  
 
 
2.3. Recruitment 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
10
2.3.1. Key entry criteria 
Key inclusion criteria:  
1. Major depressive disorder (DSM-IV) 
2. Depression of moderate to severe degree (17+ on the 21-item HAM-D). 
2. No MRI contraindications 
3. No SSRI contraindications  
4. Has a GP or other mental healthcare professional who can confirm diagnosis 
5. 18-80 years of age 
6. Males and females 
7. Sufficiently competent with English language 
 
Key exclusion criteria:  
1. Current or previously diagnosed psychotic disorder 
2. Immediate family member with a diagnosed psychotic disorder 
3. Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, 
severe cardiovascular disease, hepatic or renal failure e.g. CLRC < 30 ml/min etc.) 
4. History of serious suicide attempts requiring hospitalisation. 
5. Significant history of mania (determined by study psychiatrist and medical records) 
6. Psychiatric condition judged to be incompatible with establishment of rapport with therapy 
team and/or safe exposure to psilocybin, e.g. borderline personality disorder 
7. Blood or needle phobia 
8. Positive pregnancy test at screening or during the study, women who are planning a 
pregnancy and/or women who are nursing/breastfeeding.  
9. Participants who do not agree to use an acceptable contraceptive method throughout their 
participation in study (see section 7.2.1). 
10. Current drug or alcohol dependence 
11. No email access 
12. Use of contraindicated medication 
13. Patients presenting with abnormal QT interval prolongation at screening or with a history 
of this (QTc at screening above 440ms for men and above 470ms for women) 
 
2.3.2. Drug interactions [86] 
- Specifically for escitalopram: 
MAOIs (escitalopram should not be started until 2 weeks after stopping MAOIs, and MAOIs 
can not be started until one week after stopping escitalopram), TCIs, Amiodarone, 
Artemether with Lumefantine, Artenimol with Piperaquine, Chloroquine, Cimetidine, 
Disopyramide, Dronedarone, Erythromycin, Haloperidol, Metoprolol, Mizolastine, 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
11
Moxifloxacin, Pentamidine Isetionate, Phenothiazines, Pimozide, Quinine, Sotalol, 
Sumatriptan. Caution with Omeprazole (increases plasma concentration of escitalopram), 
and Metoprolol (escitalopram increases plasma concentration of metoprolol). 
 
- Additional for SSRIs in general – and thus also for escitalopram: 
5HT3-receptor antagonists, Antiepileptics, Aspirin (should be avoided), Coumarins, 
Cyproheptadine, Dabigatran, Dapoxetine, Duloxetine, Fentanyl, Lithium, Methylphenidate, 
Methylthioninium, Metoclopramide, NSAIDs (should be avoided), Naratriptan, Pimozide, 
Rasagiline, Ritonavir, St John’s Wort, Tramadol, Vortioxetine.  
 
Patients currently receiving any of these medications will either be asked to discontinue them 
in an appropriate way (where indicated), or they may be excluded from the trial. 
 
Contraindicated medications for escitalopram include [86, 87]: 
- MAOIs 
- Procarbazine 
- NSAIDs (including) Aspirin should be avoided during the course of the trial, as they may 
cause GI bleeding [86]. 
- Medicines that prolong QT interval, including [99]: 
• 
Cardiac medications: Class 1a (Quinidine, Procainamide, Disopromide) and Class III 
(Dofetilide, Ibutilide, Sotalol) Antiarrythmic drugs 
• 
Antihistamines (Terfenadine, Astemizole) 
• 
Antipsychotics: Haloperidol, Droperidol, Thioridazine, Sertindole*, Ziprasidone, 
Risperidone, Zimeldine, Chlorpromazine 
• 
Antidepressants: Citalopram, Amitriptyline, Desipramine, Imipramine, Maprotiline, 
Doxepin, Fluoxetin 
• 
Antibiotics: Quinolone (Sparfloxacin, Levofloxacin, moxifloxacin, grepafloxacin) and 
Macrolide (Erythromycin, Clarithromycin) 
• 
Antimalarials (Quinine, halofantrine) 
• 
Antiprotozoal (Pentamidine) 
• 
Antifungal (Azole group) 
• 
Antimotility agents (Cisapride) 
• 
Methadone 
Antipsychotic medications and mood stabilisers may attenuate the effects of psilocybin and 
so are also contraindicated for this reason. However, such medications are usually only 
prescribed for manic and/or psychotic illness, and patients presenting with such histories 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
12
would be excluded from the study. Details regarding discontinuation of antidepressant 
medications can be found below (2.4.1).  
 
 
2.3.3. Recruitment strategy 
To minimise/address pre-study biases, recruitment will predominantly be via referrals (we 
have good links with Clinical Research Networks (CRNs), Improving Access to Psychological 
Therapies (IAPT), local clinics and clinicians) and Clinical Record Interactive Search systems 
(CRIS Health Ltd). A Facebook page has also been created for the trial in order to aid 
recruitment, which will be managed by the team: https://www.facebook.com/Psilodep-RCT-
334207224132116/. Prior attitudes to treatments will be collected at baseline and entered into 
regression analyses. Patients will be randomly allocated to one of the two conditions after 
eligibility is confirmed post screening. We will endeavour to recruit patients who are currently 
unmedicated for their depression. Where patients are medicated, withdrawal from 
antidepressants would be required prior to participation and this process would be done with 
adequate washout and appropriate titration and carefully monitored in collaboration with the 
patient and their primary care giver 
 
2.4 Ethical considerations  
Similar ethical considerations will apply to this trial as applied in our feasibility study with 
psilocybin, with the additional consideration that half of the patients will receive two 
psychedelic doses of psilocybin (i.e. 25mg), 3 weeks apart, the first one followed by daily 
placebo for 6 weeks, and half will receive two inactive doses of psilocybin (1mg), 3 weeks 
apart, the first one followed by 6 weeks of daily escitalopram (10mg for three weeks and 20mg 
for three weeks). Knowledge gained from our feasibility study [1], discussions with researchers 
leading other randomized control trials in this area [5] and previous clinical trial literature on 
escitalopram [98] has directed the design of this trial.  
 
The main study risks include: standard risks associated with an acute high dose of psilocybin 
(e.g. potential acute anxiety and the need for psychological support and supervision during 
the experience), standard side-effects associated with escitalopram (e.g. drowsiness, 
dizziness, sleep problems and potential for withdrawal symptoms upon cessation), and 
standard concerns regarding placebo treatment in depression [7]. Establishing a good 
connection with referring clinicians, and following standard procedures for psilocybin research 
[70], will help to manage and mitigate its particular risks. 
 
2.4.1 Managing risks related to withdrawal from antidepressants 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
13
Serotonergic antidepressants are known to attenuate the acute psychological effects of 
psychedelics [8] and thus, we feel it is necessary that patients withdraw from these 
medications in order to experience the full effects of the 25mg dose of psilocybin. This washout 
component of the design is consistent with our recent pilot study, as this was done safely and 
effectively in that trial. Withdrawal symptoms and a worsening of depressive symptoms can 
occur with antidepressant-withdrawal [9]; thus, we will incorporate a number of contingency 
measures to reduce associated risks, namely:   
 
1) Patients will be free to leave the study at any point and return to their treatment as usual if 
they, their mental-health care-giver or the study team feel this is the right course of action. 
2) The study blind will be broken at 6-weeks after the initial dosing session (fig 1), enabling 
patients to return to pre-study treatment/s if they so choose. 
3) Study clinicians will offer telephone contact to patients during the withdrawal period, if this 
is required.  
 
It is important to note that since recruitment to this trial is not restricted to patients with 
treatment-resistant depression, potential volunteers may well be unmedicated at the time of 
study entry. Thus, we can anticipate that challenges relating to withdrawal from medication 
will be less than in our previous open-label trial in treatment-resistant depression. Even so, 
antidepressant medication withdrawal was managed safely and effectively in that trial and we 
foresee that the same will be true in this trial.  
 
2.4.2 Managing risks related to psychedelic treatment 
Before, during and after the dosing sessions, patients will receive psychological support from 
clinicians with experience of providing psilocybin treatment in the context of research studies, 
including clinical trials. On the dosing day, patients will only be allowed to return home once 
the study psychiatrist is confident they are fit to do so, and signs the patient out. Taxis will be 
ordered to take patients home. Patients will be asked to text or call us when they return home.  
 
We will ask that the patient have a friend or family member at home, when they return. We will 
ask for this ‘chaperone’s’ contact details so that we can contact them if we cannot manage to 
contact the patient themselves.  
 
Both the patient and their chaperone will be encouraged to contact us should any problems 
arise. In this way, any concerns in the immediate period or thereafter can be easily brought to 
our attention. Twenty-four-hour emergency contact numbers will be provided.  
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
14
Overnight accommodation facilities are available onsite at Imperial, which are booked in 
advance. Patients who do not have a chaperone at home will be encouraged to take 
advantage of the onsite accommodation. Similarly, patients who travel to us from outside of 
London will be encouraged to take advantage of the onsite accommodation and a friend or 
family member can also be accommodated.  
 
 
2.5 Procedures  
The patient’s immediate care team will be made aware of the study and will identify a patient 
and ask them if they are willing to be contacted by us. The primary caregiver will then inform 
us of any patients who are interested in participating and provide a contact telephone number 
and/or email. The patient will be issued with an A4 summary sheet containing a brief summary 
of the study and our contact details. The more comprehensive information sheet will also be 
made available to them. After the patient has initiated contact with us, we will inform them of 
the nature of the study and organise an appropriate time for an initial telephone screen. We 
will ask the patient if we can contact their GP/psychiatrist and this will be done via an email 
using a standard letter template.  
 
Eligibility will be principally determined by the study psychiatrist who will thoroughly screen all 
patients to identify and confirm the presence of major depression and exclude other 
conditions. Supporting information from relevant mental health professionals and/or general 
practitioners will be sought prior to entry into the trial to confirm diagnosis and ensure that all 
patients meet the inclusion criteria. 
 
If the patient appears to be eligible (post-telephone screen and post-contact with their 
GP/psychiatrist), a date for the first screening visit will be arranged. This will be a meeting with 
the study psychiatrist to review patient history, current symptoms, and to further check 
inclusion and exclusion criteria.  
 
There will be around 4 weeks from first screening visit to the first study day visit to allow 
analysis of screening data (e.g. blood tests) to determine eligibility and enable contact to be 
made between their GP and/or mental health practitioners, and so that proper and cautious 
washout of antidepressant (4 weeks for fluoxetine and 2 weeks for other antidepressants) can 
be done, where applicable. If no medication washout is required, the time from screening to 
study day one can be shorter than 4 weeks, although we will strive to acquire weekly QIDS 
ratings as soon as the patient’s entry into the trial is confirmed.  In cases where medication 
washout is required, if symptoms show a marked increase in relation to the cessation/tapering 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
15
of medications, we will discuss with the patient and their GP or mental health caregiver 
whether the patient should withdraw from the trial so that previous medications can be 
resumed or new ones given. There will be ~7 weeks from the first (post-screening) study visit 
(visit 2, scan 1) to the primary end point/blind broken (visit 7), after which patients may return 
to their normal treatments if they so wish.  
 
Patients will be required to make 7 visits (see fig. 2). Patients will be assessed for up to six 
months after the initial dosing session; however, the study blind will be broken 6 weeks after 
the dosing session. Treatment as normal can then take place after the study blind has been 
broken.  
 
2.6. Visits 
Visit 1: Screening 
Screenings typically take up to 4.5 hours and include a physical examination by the study 
doctor, an ECG, and a period of MRI scanner acclimatisation, i.e. the patient will be invited to 
spend a period lying in an MRI scanner to assess whether they can tolerate the 
environment/conditions. Consent to enter the study will be sought from each participant after 
a full explanation has been given, the study information sheet has been issued and time 
allowed for consideration. Signed informed consent will be obtained for each patient. 
We will know whether or not the patient is eligible for the trial ~3-days post screening 
(depending on receipt of relevant confirmation of diagnosis from the patient’s GP or 
psychiatrist). As soon as eligibility is confirmed, the patient will be randomly allocated to one 
of the two study conditions.  
If eligible, and if the patient wishes to participate in the trial, as soon as study entry is 
confirmed, a patient taking antidepressant medication will be required to begin coming off this 
medication, in a gradual, tapered fashion. We will ask that they inform their primary care giver 
of their decision to do this and we will manage medication withdrawal with their awareness. 
Medication withdrawal is typically done via gradual titration (e.g. halving of dose in first week) 
and the study psychiatrist will oversee this process in correspondence with the patient’s GP 
and/or psychiatrist.  
As soon as entry into the trial is confirmed, patients will be asked to complete the weekly 
QIDS-16 [12].. Patients will complete this up until the 6-week post dosing day, when the blind 
is broken. Use of the QIDS-16 [12]  will enable us to track patient’s mental health for the 
duration of the trial, facilitating patient monitoring and safety, while providing potentially useful 
data on weekly mood cycling pre versus post treatment [42].  

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
16
Blood will be collected at baseline for the following routine blood tests: 
- 
Full Blood Count (haemoglobin, total white cell count, lymphocytes, neutrophils, 
platelets) 
- 
Renal panel (creatinine, urea, estimated GFR) 
- 
Biochemistry (Sodium, potassium, adjusted calcium, phosphate, albumin and total 
protein) 
- 
Liver panel (total bilirubin, alanine transaminase, GGT) 
- 
Amylase 
We will exclude participants on the basis of a clinical significant abnormality in any of the 
above tests at screening. In particular, we will aim to exclude participants with any form of 
renal or hepatic impairment, in accordance with the cautions raised in the escitalopram SmPC 
[100], see section 7.2.1. 
As well as collecting blood for the above, we will also ask participants if we can acquire a 
sample for subsequent genetic analysis (not required for enrolment, only encouraged). Whole 
blood for genetic analysis will be collected in 2 x 8.5ml ‘PAXgene’ tubes and frozen at -20C. 
At the end of the study, samples will be transferred to the labs of the MRC Social, Genetic & 
Developmental Psychiatry (SGDP) Centre at The Institute of Psychiatry, Psychology and 
Neuroscience (IoPPN) in Denmark Hill, South London, with whom we have a material transfer 
agreement. Dr James Rucker and Dr Gerome Breen will act as custodians for the samples 
and both tissue bank and HTA licenses are already in place. The samples will be stored in 
locked -80C freezers in the SGDP labs, to which access is only given to authorised personnel 
and with full audit capabilities. 
The purpose for collecting whole blood is to enable genetic analysis in the longer term. 
Candidate gene and genome wide association analyses require high numbers of samples to 
achieve adequate statistical power in analysis. Therefore, these samples form the first batch 
of a larger sample acquisition effort in this area. Our main aim is to perform association testing 
between functional polymorphisms of the 5-HT2A receptor, hypothesising that these may be 
associated with response to treatment. For example, the T102C polymorphism of the 5-HT2A 
receptor has been associated both with suicidality in depression [92] and schizophrenia [93] 
raising the interesting question of whether the 2 alleles at this locus may have a bidirectional 
association with response to psychedelics. 
Whole blood samples for genetic analysis will be stored for up to 5 years in the first instance, 
however this will be subject to renewal depending on the progress of the wider project. 
Participants may request that their samples be destroyed at any time by notifying the PI of the 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
17
study in writing. Samples would then be destroyed by incineration. Participants will not receive 
results of genetic testing, as candidate gene analysis is vanishingly unlikely to have any 
clinically significant outcome for individuals. 
 
Visit 2: Scan 1/Prep  
The scanning procedure takes approximately 2.5 hours, with the scan itself lasting for no 
longer than 90 minutes. The scan session will be followed by psychological preparation with 
the therapy team (two individuals) who will sit with the patient during their dosing session. 
Psychological preparation will take approximately 3 hours, with two breaks. This visit will take 
approximately 5.5 hours in total.  
 
Visit 3: Dosing session 1 
The dosing session will take place the day after scan 1. Depending on the results of 
randomisation, the patient will receive either 25mg (conditions 1) or 1mg psilocybin (condition 
2) in the morning. After their dosing session is over, they will be given either placebo capsules 
(condition 1) or 10mg escitalopram capsules (condition 2) to take home with them. The dosing 
day will typically run for ~8 hours and involve: arrival at 9am, initial preparation, including 
relaxation techniques. Dosing at 10:30am. Drug effects (25mg only) are typically experienced 
for 5-6 hours (i.e. subsiding to a low-negligible level at 3:30-4:30pm). Depending on the 
magnitude of residual drug effects, patients will be asked to complete questionnaires from 
3:30pm onwards and take part in a filmed and audio recorded structured interview at 
~4:30/5pm (consent for this is included in the consent sheet – and with consent, all visits will 
be filmed as default). A study psychiatrist will assess the patient for potential discharge. If the 
patient is to travel home, a taxi will be ordered. Patients will typically leave the study centre 
around 5:30/6:00pm.  
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
18
 
Fig 2. Dosing day timeline 
 
At the end of the first dosing session, patients will be given a course of capsules to be taken 
daily (upon waking) for the following 6 weeks. Randomisation will determine whether these 
capsules are to be escitalopram or placebo. Patients will be asked to take their first capsule 
as close to 8:00am as possible  the morning after the first dosing session and document 
exactly when it was taken, to ensure standardisation of peak plasma concentration where 
relevant (i.e. escitalopram condition). N.B. peak plasma concentrations of escitalopram are 
reached 3-4 hours post-ingestion [10]. Each patient will take one capsule each day for the first 
3 weeks and two for the remaining 3 weeks, regardless of whether they are in condition 1 or 
2.  
 
Visit 4 (time since first dosing session = 1 day) 
One day after dosing, patients will be asked to complete some questionnaires (including a 
daily version of the QIDS [82]) and will also take part in a structured interview/integration 
session. Patients will be asked about their experiences the previous day, how they slept, how 
they have felt today etc. This visit will take approximately 2-3 hours in total.  
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
19
Interim period (1 week post-treatment): phone call or Skype/Zoom session to check in 
with patient. Remote assessments of the QIDS also done weekly throughout the trial. 
Assessments will be cued via email and/or text (using the Psychedelic Survey platform) and 
completed electronically (on Survey Gizmo), where the study team can access them.  
 
Visit 5 (time since first dosing session = 3 weeks): Dosing session 2  
The second dosing session will take place exactly as described in Visit 3/Fig 2 above.  
 
Interim period (4, 5 and 6 weeks post-dosing session 1): remote assessments will continue 
as before, cued via email and/or text (using the Psychedelic Survey platform) and completed 
electronically (on Survey Gizmo), where the study team can access them. Patients are free to 
communicate via email with the study team at any point if issues arise. If additional support is 
needed, each patient will be allowed a maximum of two additional Skype/Zoom sessions with 
the study team. This limit is in place in order to avoid an imbalance in the amount of support 
patients receive. 
 
Visit 6 (1 day post-dosing session 2):  
This visit will follow the same structure as visit 4 (1 day post-dosing session 1), described 
above. 
 
Visit 7 (time since first dosing session = 6 weeks/time since second dosing session = 
3 weeks) 
The final study visit will take place 6 weeks after the first dosing session. This visit will include 
a final MRI scan.  Patients will arrive at 10am and be scanned at 11am. The scanning session 
will last for no longer than 90 minutes. After this, patients will be asked to complete some 
questionnaires and will take part in a structured interview in which they will be asked how they 
have felt today and the past 6 weeks. The HAM-D and MADRS assessments will be performed 
which enquire about depressive symptoms over the last week. A comprehensive side-effects 
questionnaire will also be completed, which asks about side-effects over a 6-week period [11]. 
A second ECG scan will also be conducted in order to ensure no effect of either drug on heart 
physiology and a repeat routine blood test will be done (see above for a complete list of 
tests).This visit will take approximately 5 hours in total. At the end of this visit, we will inform 
the patient of the condition they were enrolled in; thereby breaking the blind. Breaking the 
blind at this time point will enable us to assess treatment safety and efficacy for both conditions 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
20
and provide the patient with information on what they have received - which may then inform 
future decisions regarding treatment, e.g. whether or not they want to continue with 
escitalopram if they were in condition 2.   
 
Study Timeline 
Date 
Event 
Main 
assessment/s 
Approximate Duration 
Visit 1 
Screening 
QIDS, HAM-D 
MADRS, ECG 
5 hours 
Visit 2 
Scan 1 
QIDS, HAM-D, 
MADRS, scan 
measures 
5 hours 
Visit 3 
Dosing session 
1 (DS1) 
ASC, EDI, etc 
8 hours 
Visit 4 
1-day post DS1 
QIDS, interview 
2-3 hours 
Visit 5 
Dosing session 
2 (DS2) 
ASC, EDI, etc 
8 hours 
Visit 6 
1 day post DS2 
QIDS, interview 
2-3 hours 
Visit 7 
Final visit + 
scan 2 
QIDS, HAM-D, 
MADRS interview, 
ECG, scan 
measures 
5 hours 
6-weeks post 
DS1 
 
At the end of Visit 7: patients will be told by the study team that a documentary is being made 
about the study that they could participate in if they chose to. If they are interested in finding 
out more information, they will be taken to meet the Imperial Press Office team in person. The 
Imperial Press Office team will talk to them about the nature of the documentary and the 
implications of participating. Participants will be given an information sheet/consent form to 
read and sign if they are interested, as well as an information sheet about the film producers 
Grain Media. If participants are keen to be involved or would like to find out more, they can 
also meet the Grain Media team in person, who can tell them more about the documentary 
process. If participants agree to sign the consent form, this will prompt the study team to 
release the footage that has been filmed in the trial to Grain Media. If participants choose to 
not sign, the footage remains only for use within the Imperial team (the data ‘controllers’), for 
training purposes, as agreed in the initial consent form signed at the start of the study (unless 
further consent to share is sought from patients).  
Assessments at 1-6 months Visit 7: remote assessments of the QIDS-16 will be done 
monthly at 1-6 months post-treatment. More comprehensive assessments will also be done 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
21
1, 3 and 6 months after the initial dosing session. Assessments will be cued by telephone and 
email and completed electronically and emailed back to the study team. A member of the 
study team will speak with the patient via telephone or skype at these time points.   
1 month post Visit 7: A structured interview will be carried out via Skype, telephone or in 
person if the patient prefers this. This will focus on the patient’s overall experience of the trial, 
looking back on it as a relatively recent experience, and on how they are doing 1 month later. 
 
6-months post Visit 7: Remote assessments will be done (as at 3 months) and a structured 
interview will be carried out and recorded, either via skype, telephone or in person, if the 
patient prefers. This will focus on the patient’s perception of the value of the trial with the 
benefit of 6 months of hindsight and on how they are doing now. See Appendix 1 for semi-
structured interview protocol.  
 
If, at any point after the final formal study visit, we become concerned about a patient’s mental 
state and associated risks, we will liaise with their GP and/or mental health practitioners - who 
may then decide to implement appropriate interventions, if this is indicated.      
 
2.7. Psychological outcome measures  
Measures completed before and after treatment will include the following: 
o QIDS-16 (primary efficacy outcome measure) [12] 
o QIDS-16 (daily measure) [82] 
o BDI II (two-weekly measure) [13] 
o HAM-D [14]  
o MADRS [34] 
o Spielberger’s Trait Anxiety Inventory (STAI) - Trait [15] 
o Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) [16] 
o Flourishing Scale (FS-8) [102] 
o Snaith Hamilton Anhedonia Pleasure Scale (SHAPS) [17] 
o Life Orientation Test (LOT-R) [18] 
o Meaning in Life Questionnaire (MLQ) [19] 
o Brief Resilience Scale (BRS) [20]  
o Dysfunctional Attitudes Scale (DAS) [21]   
o 44-item Big Five Inventory [22] 
o Peters 21-item delusional inventory (PDI) [23] 
o EASE anomalous subjective experience [24] 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
22
o Ruminative Responses Scale (RRS) [25] 
o White Bear Suppression Inventory (WBSI) [26] 
o Barrett Impulsivity Scale (BIS) [27] 
o Brief Experiential Avoidance Questionnaire [28]  
o Modified Tellegen Absoprtion Questionnaire (MODTAS) [29]  
o Scale To Assess the Therapeutic Relationship (STAR) [30] 
o Credibility/Expectancy Questionnaire [31] 
o Connectedness to Nature Scale (CNS) [32] 
o Political Perspective Questionnaire (PPQ) 
o Social Connectedness Scale (SCS) [33] 
o Bech-Rafaelsen Mania Rating Scale (MAS/MRS) [34] 
o Revised Santa Clara brief compassion scale (5 items) (SCBCS) [35] 
o Gratitude Questionnaire (GQ-6) [36] 
o Short Suggestibility Scale (SSS) [37] 
o Self-esteem: Rosenberg Self-Esteem Scale [4-items] (RSE) [38] 
o Universality subscale of the Spiritual Transcendence Scale (STS) [39] 
o Oxford Questionnaire on the Emotional Side-effects of Antidepressants (OQuESA) [40] 
o Lauks Emotional Intensity Scale (LEIS) [41] 
o The Suicidal Ideation Attributes Scale (SIDAS) [84]  
o Sexual dysfunction (PRSEXDQ-SALSEX) [83] 
o Selected items from Brief lndex of Sexual Functioning for Women (BISF-W) [104] 
o 2-item Sexual Perceptions Questionnaire (SPQ, self-constructed) 
o Barnes Akathisia Rating Scale (BARS) [85] 
o Work Productivity and Activity Impairment Questionnaire (WPAI) [87] 
o The Work and Social Adjustment Scale (WSAS) [88] 
o Self-constructed Connectedness Questionnaire 
o Standard Assessment of Personality – Abbreviated Scale (SAPAS) [96] 
o Positive and Negative Syndrome Scale (PANSS) [97] 
o Mastery Insight Scale (MIS, taken from Therapeutic Realisations Scale [103]) 
o Self-Reflection and Insight Scale (SRIS) [106] 
o Psychological Insight Scale (PIS, self-constructed) 
o Metaphysical Beliefs Questionnaire (MBQ, self-constructed) 
o Spiritual Bypassing Scale (SBS, self-constructed) 
o Adverse Childhood Experience Questionnaire (ACE) [105] 
o Therapeutic Music Experience Questionnaire (TMEQ, self-constructed) 
o Setting Questionnaire (SQ, self-constructed) 
o Selected Items from the Absorption in Music Scale (AIMS - revised) 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
23
o Acceptance and Action Questionnaire (AAQ-II) [107] 
o CompACT Questionnaire [108] 
 
Although there are a large number of these measures, they are intentionally brief. It will take 
approximately 75 minutes to complete them. Patients will be encouraged to do this in two or 
more ‘stints’ and to take a break if/when they become tired and lose focus.   
 
Measures completed just before treatment will include the: 
o Spielberger’s Trait Anxiety Inventory (STAI) - State [15] 
o The psychedelic predictor scale (self-constructed) 
o The surrender scale (self-constructed) 
 
Behavioural tasks will include: 
 
o Emotional processing battery [88] 
o Cued autobiographical memory task (AMT) [44]  
o Prediction of Future Life Events (POFLE) [45] 
o Torrance Test of Creative Thinking (TTCT) [46] 
o Emotional response to music [89] 
o California Verbal Learning Test  (CVLT) [90] 
o Digit Symbol Substitution Test (DSST) [91] 
 
The following scales will be used to measure subjective states during the dosing sessions to 
be filled out at the end of the dosing session: 
 
o Ego Dissolution Inventory (EDI) [47] 
o Mystical Experience Questionnaire (MEQ) [48] 
o 11 Dimension Altered States of Consciousness Scale (11D ASC) [49] 
o Psychotomimetic States Inventory (PSI) [50] 
o Visual Analogue Scales (VAS) 
o Geneva Emotional Music Scales (GEMS) [51] 
o The Challenging Experience Questionnaire [52] 
o The Imperial Emotional Breakthrough Inventory (EBI)  
o Near-Death Experience (NDE) scale [53] 
o Ten Item Personality Inventory (TIPI) [88]  
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
24
With prior consent, we will also send a patient’s significant other a short questionnaire at 
baseline and at the 6-week end point to enquire how they perceive the patient’s depression 
and whether they have noticed any changes in the patient’s behaviour since the intervention. 
 
2.8. Scanning outcome measures 
o BOLD response to emotional faces (primary fMRI outcome measure) 
o Resting state blood oxygen level dependent (BOLD) signal scan  
o Resting BOLD with music as hedonic stimulus 
o Anatomical scans (T1 & T2) 
o Diffusion Tensor Imaging (DTI) scan 
 
3. Basic safety and scientific background  
The LD50 of psilocybin in rats is 280mg/kg [54]; thus, in terms of toxicity, its margin of safety 
is very large. We intend to give no more than 25mg which equates to less than 0.3 mg/kg. 
Doses of 30mg and higher have been used in previous research with healthy volunteers and 
patients without serious adverse events [55; 56]. Common adverse events with high doses of 
psilocybin include sub-acute headaches which last for 1-2 days maximum, and acute anxiety, 
which subsides with psychological reassurance or as the acute drug effects subside [1]. 
Psilocybin has been given to several hundred patients and volunteers in modern studies. In a 
thorough review of dosing sessions in 110 healthy subjects, dysphoric experiences/bad trips 
were rare and dose-dependent. Moreover, there is no evidence of subsequent drug abuse, 
flashback phenomena or prolonged psychoses [57]. We observed no cases of persistent 
adverse effects of psilocybin in our recent trial of psilocybin for depression in 20 patients. 
Psilocybin is not habit forming in animals or humans [58] and none of the patients expressed 
craving for psilocybin.   
 
Reports from the 1960s on the use of psilocybin in psychotherapy indicate clear benefits over 
harms [59]; however, these studies suffer from a lack of experimental control and standardised 
assessments. More recently, pilot studies have tested the efficacy of psilocybin in OCD [60] 
and anxiety related to terminal cancer [3]: In the former study, short-term reductions in 
compulsive symptoms were reported by all of the patients. In the latter study, trait anxiety was 
significantly decreased 1 and 3 months post session and depression scores were significantly 
decreased at 6 months. No clinically significant adverse events were observed in either study. 
In a large sample of healthy volunteers, orally administered high dose psilocybin induced 
mystical or spiritual-type experiences in over 60% of subjects [56]. 67% rated their experience 
as either the single most meaningful experience of their lives – or among the top five. In a 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
25
follow-up after 14 months, 64% of the sample maintained that the acute experience had led 
to a significant improvement in their sense of well-being or life satisfaction [61].   
 
In the last four years, we have completed one pilot study [62], two fMRI studies [63] and one 
MEG study involving psilocybin [64], as well as a pilot study in treatment resistant depression 
(n = 20) [65]. We have carried out around 100 dosing sessions in total most with a dose 
equivalent to that proposed here and have seen no serious adverse events.  
 
4. Study design 
4.1. Primary outcomes 
4.1.1 Primary outcome measure and endpoint 
The primary fMRI outcome will be change in amygdala BOLD response to emotional faces 
from baseline (prep, 1 day pre-DD1) to scan 2 at 6-weeks post-DD1. Change after psilocybin 
(condition 1) vs change after escitalopram (condition 2). 
 
4.1.2. Primary efficacy outcome measure and endpoint 
Change in QIDS score from baseline (screening) to 6 weeks post initial dosing session 
(primary endpoint). Change after psilocybin (condition 1) vs change after escitalopram 
(condition 2). The criteria for determining response will be a reduction of 50% in the QIDS 
scores and remission will be scores of ≤5 on the QIDS, as per convention [12]. 
 
 
 
 
 
 
4.2. Volunteers  
4.2.1. Sample size 
A baseline versus 5-weeks post-treatment reduction of -9.2 (SD = 5.6) on the QIDS was 
observed in our recent pilot study. To inform what can be expected with 1mg psilocybin, we 
can refer to the recent end-of-life anxiety trial of Griffiths et al. [66] in which the reduction in 
scores on another standard scale (BDI) seen with the control condition (1-3mg/ 70kg 
psilocybin) was 50% that of the active condition, i.e. a reduction of 10.7 (22-30mg/70kg, active) 
versus 5.5 (1-3mg/70kg, control) at 5-weeks post-treatment. If 1mg psilocybin is equally as  
effective as the 1-3mg/70kg in the Griffiths study, i.e. 50% of the active dose (which is 
a conservative prediction, given that the difference in doses is greater, and the time since 
treatment is shorter), we can expect a mean reduction in QIDS scores of 9.2/2 = 4.7 points for 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
26
the 1mg condition. If we assume equal variance for both conditions, we would require 20 
patients per condition to achieve the desired power of 80%, p < 0.05. We therefore propose 
to recruit a minimum of 30 patients per condition (60 completers in total for the RCT). These 
are appropriate numbers for the imaging, given that significant baseline v one-day post-
treatment effects are being observed in BOLD resting-state functional connectivity, amygdala 
activations to emotional faces and CBF with just 15 patients in my recent pilot study (papers 
in preparation). Significant fMRI findings have been reported with escitalopram in similar 
paradigms and with similar sample sizes [67]. Equivalent efficacy (primary outcome) is 
predicted for the escitalopram vs 25mg psilocybin conditions but with different mechanisms of 
action. For example, we predict greater improvements in wellbeing (WEMWBS) with 25mg 
psilocybin vs escitalopram at 6-weeks post dosing day 1.  
 
4.2.2 Recruitment of volunteers 
Regarding recruitment, we will endeavour to recruit via referrals. We have good links with a 
number of potential referring centres. We will also utilise word of mouth however, as we did 
effectively in our previous trial.  
 
We will aim to recruit a similar number of male and female patients. Patients will be at least 
18 years of age with an acceptable level of physical health as determined by a medical 
screening that will include: routine blood tests, ECG, blood pressure and heart rate, 
neurological exam and psychiatric assessment (MINI). Patients with cardiovascular 
abnormalities, epilepsy, personal or family histories of psychosis or psychotic symptoms 
(including mania), or histories of suicide attempts, will not be allowed to participate. As in 
previous trials, we will include patients that have previous experience with psychedelic drugs, 
although it is anticipated that most will have never had an experience with a psychedelic. All 
patients will have a good command of the English language. Patients will have HAM-D scores 
of at least 17.  
 
General practitioners will be contacted in every case to inform them of the details of the trial 
and to enquire whether they have any concerns about their patient entering the trial. Until we 
have confirmed their background medical and psychiatric history, patients will not be allowed 
to enter the trial. Psychiatric diagnosis is principally determined by one of our study 
psychiatrists but confirmation will be sought in every case from past/current practioners and a 
decision will need to be made by the study clinical team about persisting with a given patient 
if confirmation of diagnosis is not initially forthcoming. In our recent pilot study, patients were 
successful at obtaining their medical records from their GP, but this can take time and so incur 
delays.  

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
27
 
4.2.3 Screening procedure: Initial screening visit 
1. Informed consent 
2. Full history-taking and physical examination 
3. Psychiatric assessment (MINI) 
4. Routine blood screen and sample 
5. ECG 
6. Urine drug screen  
7. Urine pregnancy test if woman of childbearing potential (see section 7.2.2) 
8. Height & weight recorded 
9. Breathalyser 
10. Completion of clinician administered rating scales (HAM-D) 
11. Completion of secondary outcome measures  
  
4.2.4 Withdrawal Criteria 
1. Withdrawal of Consent 
2. Development of concurrent physical illness that necessitates their removal from the trial 
3. Deterioration of mental health warranting additional input and support 
4. Dependency or problematic alcohol or illicit substance use 
5. Positive pregnancy test in women of childbearing potential (see section 7.2.2) at any point 
during study 
 
GPs and all relevant health professionals will be informed of their patient’s involvement in the 
trial. Any misgivings or reservations they have about their patient entering and continuing the 
trial can be responded to by the study psychiatrist.  
 
On entering the trial, should there be any deterioration in the patient’s physical or mental health 
that may compromise their ability to continue in the trial then we will reach an informed 
decision, once we have the contacted the relevant health professionals, about whether their 
continued participation is prudent. This will all be done in discussion with the patient and the 
extended research team.  
 
 
5. Regulatory Issues and informed consent 
5.1 Ethical Approval 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
28
The study will be conducted according to the revised declaration of Helsinki (2000), the 
International Committee on Harmonisation Good Clinical Practice guidelines and NHS 
Research Governance Framework. Ethics and R&D approval will be obtained.   
 
5.2 Consent 
Consent to enter the study will be sought from each participant after a full explanation has 
been given, the study information sheet has been issued and time allowed for consideration. 
Signed participant consent will be obtained for each patient. It is the right of the patient to 
refuse to participate without giving reasons and this will be respected. All patients are free to 
withdraw at any time from the study without giving reasons and without prejudicing their further 
treatment. 
 
5.3 Confidentiality 
Patient’s identification data will be required for the registration process and will be held in the 
screening CRF only. The research team will maintain patient confidentiality at all times. 
Unique, anonymous patient identifiers will be issues after screening when a patient is enrolled 
in the study. Identifiers will be issues in a regular ordinal manner, e.g. P1, P2, P3 etc. and 
these identifiers will be issued to the manager of the randomisation (Invicro, previously 
Imanova) to determine the relevant condition and task/test versions for each patient (see 
randomisation, section 12).  
 
5.4 Audits and Inspections  
The study may be subject to inspection and audit by Imperial College London and/or Imperial 
College Healthcare NHS Trust under their remit as sponsor and other regulatory bodies to 
ensure adherence to GCP. 
 
 
5.5. Monitoring 
The study will be monitored internally by the Centre for Neuropsychopharmacology, through 
the Trust via InForm and it may also be audited by the MHRA and imperial JRCO. Any trial-
related regulatory inspections will be permitted and direct access to source data and 
documents will be provided. 
 
Prof Guy Goodwin (former President of the European College of Neuropsychopharmacology 
and British Association of Psychopharmacology) has agreed to Chair a Trial Steering 
Committee and Imperial’s Joint Research and Compliance Office (JRCO) and Clinical 
Research Facility (CRF) both conduct audits of the trial. A Data Monitoring Committee is 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
29
currently being compiled consisting of senior figures within the Centre for Psychiatry at 
Imperial. 
 
6. Patient recruitment strategy 
Primary recruitment will be via referrals from mental health practitioners working in the field 
who have knowledge of the trial and feel that their patients fulfill the inclusion criteria. This 
study will be adopted by the Mental Health Research Network (MHRN) as well as a number 
of Clinical Research Networks (CRNs). We have links with the Improvement of Access to 
Psychotherapy Treatments (IAPT) scheme which runs out of the Camden and Islington Trust. 
We will also liaise with fellow mental health practitioners working in other London Mental 
Health Trusts and in satellite towns and cities, with whom we have links. We will also use 
Clinical Record Interactive Search systems (CRIS Health Ltd). In every case, patients will be 
thoroughly screened by the study psychiatrist to ensure that they comply with our inclusion 
criteria before entry into the trial.  
 
7. Drug specific ethical and safety considerations 
7.1 Psilocybin safety 
We have run close to 100 dosing sessions with psilocybin without serious adverse event, 40 
of these were in patients with treatment resistant depression. Recent independent 
assessments of the harms of popular drugs of abuse, conducted by international experts and 
experienced drug users have consistently rated magic mushroom as one of the least harmful 
recreational drugs [68]. Commonly cited risks include: prolonged psychotic reactions, 
flashback phenomena/hallucinogen persisting perceptual disorder (HPPD), and bad trips. 
Prolonged psychotic responses are extremely rare in clinical studies with psilocybin (<1% 
[57]), even with very high doses [55], and none have been reported in modern studies or 
studies with patients. We have observed no prolonged psychotic reactions with psilocybin in 
any of our studies and acute psychotic symptoms, such as paranoia, are also quite rare. The 
risk of flashback phenomena is minimal-negligible and has no cases have been observed in 
our or other studies with psilocybin. Periods of psychological challenge, e.g. involving anxiety, 
are more common [56; 65]. Although evidence indicates that challenging experiences under 
psychedelics can be predictive of positive clinical outcomes [69].   
 
Common (>20% at 25mg):  
1) Increased anxiety, particularly at the onset of the drug effects  
2) Mild-moderate increased in heart rate 
3) Visual hallucinations 
4) Transient headaches, lasting for 1 to 2 days (max) post-dosing  

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
30
 
Less common (<15%):  
1) Paranoia or suspiciousness. 
2) Nausea  
3) Dizziness 
4) A ‘bad trip’ i.e. negative thoughts and mood during the acute drug effects 
 
Rare (prevalence unknown but likely < 2%):  
1) HPPD/flashbacks 
2) Worsening of mental state after the drug experience 
 
It is not uncommon for people to experience some negative psychological content during a 
psilocybin ‘trip’, particularly if they suffer from ongoing psychological distress, as is 
characteristic of depression. Typically, this is best deal with by good preparation and support 
during the experience and integration afterwards. In our sample of 20, while challenging 
episodes were relatively common within the patients’ trips, none were entirely characterized 
by dysphoric or distressing content, and when challenging content did arise, it was often 
worked through and contributed to a psychological ‘breakthrough’ on the part of the patient. 
Recent evidence indicates that challenging psychological experiences can produce 
therapeutic benefits, improving psychological well-being in the long-term [69].  
 
Negative aftereffects of challenging psychological experiences under psychedelics are 
thought to be a consequence of inadequate ‘set and setting’ and post-session integration work 
– and they may also relate to the duration of the challenging period [69]. We shall reduce 
these risk through good psychological preparation and integration work, good patient-staff 
rapport and a positive environment. Research and medical staff will plan carefully for such 
eventualities however. Challenging experiences/periods are best managed psychologically. 
Injectable lorazepam, as a ‘rescue medication’, will be available but would only be used in 
cases of severe panic that were unresponsive to psychological intervention, and where the 
patient’s behavior was putting themselves and/or staff in danger. Consent for such medication 
will be sought from the patient ahead of study participation. Detailed protocols are available 
on the safe management of clinical research with psychedelics [70].  
 
7.2. Escitalopram safety  
7.2.1 Side-effects and SmPC Cautions 
In a meta analysis of 22 clinical trials comparing various antidepressant medications, 
escitalopram was found to compare favourably in terms of achieving acute response, 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
31
remission of symptoms and low trial withdrawal rates [71]. As with all SSRI’s, side effects are 
commonly reported.  Specific side effects that have been associated with escitalopram 
include: 
 
Common (i.e. ~10% at 20mg): 
1) 
Agitation or restlessness 
2) 
Diarrhea 
3) 
Difficulty sleeping 
4) 
Drowsiness 
5) 
Dry mouth 
6) 
Headache 
7) 
Nausea 
8) 
Sexual difficulties (decreased sexual ability or desire, ejaculatory delay) 
9) 
Dizziness 
10) 
Sweating 
 
Less common (< 10%)  
1) 
Frequent urination 
2) 
Indigestion 
3) 
Increased or decreased appetite 
4) 
Taste alterations 
5) 
Tremor (shaking) 
6) 
Tingling in arms or legs 
7) 
Weight changes 
8) 
Influenza-like symptoms and pain in neck or shoulders 
9) 
Serotonin syndrome 
10) 
Suicidal thinking and behavior 
11) 
Abnormal bleeding 
12) 
Seizures 
13) 
Manic episodes 
14) 
Low sodium 
15) 
Angle closure glaucoma 
 
The MHRA recommends that escitalopram should not be used in patients with known QT 
interval prolongation (above 440ms in men and above 470ms in women) or in combination 
with other medicines known to prolong the QT interval. An ECG during the screening visit will 
ensure that such individuals will be excluded from the study. To prevent antidepressant 
discontinuation syndrome, gradual withdrawal from escitalopram will be managed by the study 
psychiatrist in consultation with the patient’s GP/psychiatrist.  
 
In the event of signs of cardiac arrhythmia (fluttering in chest, tachycardia, bradycardia, chest 
pain, shortness of breath, lightheadedness, etc), patients will be advised to contact us and 
their GP immediately and stop escitalopram dosing. In this case, we would schedule an extra 
visit and perform an extra ECG. 
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
32
Additionally, the Summary of Product Characteristics (SmPC) for escitalopram [100] advises 
caution in patients with severely reduced renal function (CLCR less than 30 ml/min). We are 
aiming to recruit depressed patients who are otherwise physically healthy and will be excluding 
patients with severely reduced renal function as per exclusion criteria. 
 
The SmPC for escitalopram [100] also raises cautions about its use in patients with hepatic 
impairment. In the case of mild or moderate hepatic impairment, dose reduction is necessary. 
For consistency, patients with any form of hepatic impairment will be excluded (see section 
4.2.4). Liver Function Tests (LFTs) conducted in screening will provide the study medical 
doctor with the necessary information to make this assessment.  
 
Furthermore, the escitalopram SmPC [100] highlights potential dangers of using SSRIs in 
pregnancy (especially late pregnancy) and does not recommend its use during lactation. 
Additionally, because psilocybin does not currently have a marketing authorization and has 
not undergone extensive testing in-utero and during lactation (as enforced by the HMA 
guidelines [101]), we will avoid this issue by administering pregnancy tests throughout and 
excluding any participants who test positive, are currently breastfeeding,  planning a 
pregnancy and/or are not using reliable birth control (unless they are not deemed to be of 
childbearing potential, see section 7.2.1 below and exclusion criteria for details).  
 
7.2.2 Pregnancy, Breastfeeding and Contraception                                                                    
A woman who is not of childbearing potential is considered to be postmenopausal (at least 48 
consecutive weeks without menstruation) or permanently sterilized (eg hysterectomy and/or 
bilateral salpingectomy). 
 
The following methods of contraception, if used properly and used for the duration of the study, 
are generally considered reliable: oral contraceptives, patch contraceptives, injection 
contraceptives, male condom with intravaginal spermicide, diaphragm or cervical cap with 
spermicide, vaginal contraceptive ring, intrauterine device, surgical sterilization (eg 
hysterectomy and/or bilateral salpingectomy), vasectomized partner, or sexual abstinence. 
Periodic abstinence (i.e. calendar, symptothermal, or postovulation methods and tubal 
ligation/occlusion) are not an acceptable form of contraception for this study. 
 
These methods of contraception also apply to partners of male participants. 
 
If the participant or the female partner of a male participant becomes pregnant within 30 days 
of receiving psilocybin the investigator should be notified and information will be reported to 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
33
sponsors and COMPASS Pathways, the providers of the IMP, within 24hrs of discovery. 
Although pregnancy is not technically an AE, all pregnancies must be followed to conclusion 
in order to determine outcome. This information is important for both drug safety and public 
health concerns. If any adverse event occurs in pregnancy (i.e. post-partum complications, 
spontaneous or induced abortions, stillbirth, neonatal death, or congenital anomaly, including 
that in an aborted fetus) it will be reported as an SAE. 
 
7.3 Suicide and persistent adverse events 
There have been no cases of increased suicidality in modern trials with psilocybin and we did 
not observe any such cases in our recent trial in 20 patients; in fact, mean suicidality scores 
for the sample were significantly reduced at all follow-up time points. A large population survey 
in the US found a selective association (i.e. among drugs of potential misuse) between 
psychedelic-use and reduced suicidality [72].  
 
There is some evidence of slightly increased suicidality (i.e. suicidal thoughts and behaviours) 
in adults taking SSRIs over those taking placebo [73], although not all meta-analyses have 
found this relationship [74]. Suicidality may be elevated in adolescents treated with 
SSRIs/SNRIs (i.e. from 2% with placebo to 4% with active treatment) [75] but escitalopram 
was not included in the most recent meta-analysis, and we will exclude individuals under the 
age of 18 for this trial.  
 
The risk of suicide with placebo treatment is low (0.7% suicide attempts) [76]. The risk of 
suicide will be further minimized by excluding patients with histories of suicide attempts. We 
will also give patients a study psychiatrist’s and psychotherapist’s contact number in cases of 
emergency. We have written a standard operating procedure for dealing with both adverse 
events and any unexpected suicide attempt.  
 
 
7. 4 Definitions and reporting of Adverse Events & Reactions 
1. Adverse Event (AE): Any untoward medical occurrence in a patient or clinical trial subject 
administered a medicinal product and which does not necessarily have a causal relationship 
with this treatment 
2. Adverse Reaction (AR): All untoward and unintended responses to a medicinal product 
related to any dose administered 
3. Unexpected Adverse Reaction (UAR): An AR, the nature or severity of which is not 
consistent with the applicable product information. 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
34
4. Serious Adverse Event (SAE) or Serious Adverse Reaction: Any untoward medical 
occurrence or effect that at any dose i) results in death ii) is life-threatening iii) requires 
inpatient hospitalisation or prolongation of existing hospitalization iv) results in persistent or 
significant disability or incapacity or v) is a congenital anomaly/birth defect 
5. Suspected Unexpected Serious Adverse Reactions (SUSAR): any suspected adverse 
reaction related to a medicinal product that is both unexpected and serious 
 
Most AEs and ARs that occur in this study, whether they are serious or not, will be expected 
treatment-related effects of the drugs in this study. The assignment of the causality will be 
made by the team including using the following definitions: 
 
1. 
Unrelated: There is no evidence of any causal relationship 
2. 
Unlikely: There is little evidence to suggest there is a causal relationship and there is 
another reasonable explanation for the event. 
3. 
Possible: There is some evidence to suggest a causal however the influence of other 
factors may have contributed to the event 
4. 
Probable: There is evidence to suggest a causal relationship and the influence of other 
factors is unlikely 
5. 
Definitely: There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out 
6. 
Not Assessable: There is insufficient or incomplete evidence to make a clinical 
judgment of the causal relationship. 
 
Should any uncertainty exist regarding causality, we will discuss within the team and farther 
afield with local clinicians and representatives. In the event that no agreement is made, the 
MHRA will be informed of competing points of view. 
 
 
 
7.5. Reporting Procedures 
All adverse events will be collected from signing of informed consent until the end of the study. 
Depending on the nature of the event the following reporting procedures will be followed.  
1. Non serious AR/AEs: All such toxicities, whether expected or not, will be recorded as part 
of a case report and sent to the research team within one month. 
2. Serious AR/AEs: Fatal or life threatening SAEs and SUSARs will be reported on the day 
that the research team is aware of the event. The SAE form requires nature of event, onset, 
severity, corrective treatment given, outcome and causality. Additional information will be sent 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
35
within 5 days if the reaction has not resolved at the time of reporting. An SAE form will be 
completed for all SAEs and reported to the CI/Sponsor (JRCO.CTIMP.TEAM@imperial.ac.uk) 
within 24 hours.  
3. SUSARs: Only serious and unexpected adverse drug reactions are subject to expedited 
reporting. A SAE report form will be completed by the staff at the site of where the adverse 
reaction occurred and sent immediately signed and dated to the research team with relevant 
treatment forms and anonymised copies of all relevant investigations. We will ensure that the 
MHRA, REC and the Sponsor are notified of all SUSARs occurring during the study according 
to the following timeline: fatal and life threatening within 7 days of notification and non-life 
threatening within 15 days. All investigators will be informed of all SUSARs occurring 
throughout the study. Any serious adverse events or reactions that are expected or otherwise 
will be reported to the sponsor immediately. 
 
Due to the limited safety information available for psilocybin, in addition to reporting all adverse 
events in line with the requirements of this protocol, the study team will be recording adverse 
events separately. These AEs will be transferred to Worldwide Clinical Trials for adding into a 
safety database, managed by both Worldwide Clinical Trials and COMPASS Pathways, 
allowing for the continued development of safety data around psilocybin. Patients will be asked 
to consent for this aspect of the research; patients who do not consent will not be excluded 
from study participation.  
 
  
8.  Standard Operating Procedure (SOP) for managing adverse events under psilocybin 
• 
Prior to administration of the drug, we aim to fully prepare each participant to ensure that 
they are aware what to expect. We will also ensure that they are met by all members of the 
research team. We have used this approach before and believe it to significantly reduce the 
possibility of any psychological adverse events following administration and serve to put 
patients at ease in the process. If patients know what to expect beforehand and are 
comfortable within their surroundings prior to receiving the drug, then this will reduce the risk 
of any untoward events. 
• 
Patients will be escorted and chaperoned by a member of the research team at all times 
throughout their participation in the study and for the period during which they will be under 
the acute effects of psilocybin, they will always be supported by a team member. 
• 
The acute effects of the drug subside 5-6 hours following administration; however, we will 
carefully monitor the patient for the duration of their stay at the study centre. 
• 
We do not envisage any serious side-effects from administration of the drug; however, 
patients may experience anxiety reactions or paranoid thoughts. These are likely to be short-

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
36
lived and will be managed by psychological approaches such as reassurance and adopting 
a calm and supportive manner and by using behavioural techniques such as guided imagery. 
This was used effectively in our pilot study to facilitate calm. We will also offer patients the 
opportunity for a member of the therapy team to provide reassuring ‘arm holding’. This is 
where, upon the patient’s request, a therapist will place their hand on the patient’s wrist/ arm, 
as a way of helping the patient feel secure during drug administration. This exercise will have 
been previously practiced during the preparation session. Many patients in our previous 
feasibility study reported feeling reassured by having the option of arm holding if they felt 
anxious. 
• 
In the unlikely event that a patient becomes behaviourally disturbed, and the use of de-
escalation techniques are not sufficient, medical personnel from the research team and/ or 
CRF will be on hand to administer tranquillisation if necessary. Patients will be asked to 
consent to this ahead of time. Tranquilising medication was never used in our pilot study and 
would only be used as a very last resort. 
• 
Typical doses administered would be PO 1-2mg Lorazepam initially then titrated to effect, 
but any benzodiazepine or tranquilising medication may be administered. This medical 
decision lies with the full-time trial clinicians present at the time, all ILS trained. 
• 
If such an adverse event was to occur, a member of staff will accompany the patient at all 
times and in no circumstances will they be permitted to leave the unit until the psychiatrist is 
satisfied that they are in a fit state to do so. 
• 
We foresee the majority of patients being able to return home approximately 6 hours after 
receiving the drug; however, there may be patients who we feel are not in the appropriate 
frame of mind to be discharged from the clinical research facility at that time. If this was to 
occur, a psychiatrist would remain in the department for as long as is necessary to ensure 
the patient’s recovery back to their previous level of functioning. 
• 
Prior to a patient’s discharge from the unit, an assessment of their current level of risk will 
be conducted to determine whether it is safe for them to leave. 
• 
Should we have any reservations about discharging a patient, they will be offered the option 
of an overnight stay at a nearby facility until the following day. They will be supported 
overnight by the psychiatrist and research nursing staff. 
• 
Patients will be reviewed the next morning to establish whether they have returned to their 
normal level of functioning and we will decide whether they can return home. 
• 
Phone numbers for each member of the research team will be provided to the patient and 
this responsible other to ensure immediate contact if required. We will also have contact 
details for the patient and their responsible other, if we need to be in contact.  
• 
Appropriate follow-ups are in place for monitoring the patient’s status throughout the study 
and afterwards. We will therefore be able to detect any prolonged or delayed adverse events. 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
37
• 
Patients and their relatives will be encouraged to contact us should their mental or physical 
health deteriorate. Although our options of managing their current difficulties will be limited 
after the trial is complete, we will be able to offer referral to the relevant services. If indicated, 
we will offer a further follow-up at the clinical research facility so that we can review the 
patient in person. 
 
9. Purchasing, manufacturing and storing drug 
Psilocybin free-base will be purchased and made to Good Manufacturing Practice standards 
in accordance with Medicines and Healthcare Products Regulatory Agency (MHRA) 
regulations. The drug will be stored in a secure laboratory in a locked fridge. Home Office 
permission for possession and storage will be obtained.  
 
The API psilocybin is being synthesised to GMP standard by Onyx pharmaceuticals (UK) and 
encapsulated to GMP standards by Juniper pharmaceuticals (UK) and blinded by Fisher 
pharmaceuticals (UK). This route will provide both the 25mg and 1mg doses of psilocybin for 
the dosing session. Regarding 6 weeks of escitalopram versus 6 weeks of placebo, relevant 
doses of escitalopram and placebo are to be encapsulated in accordance with GMP guidelines 
by Guys and St Thomas’ (GSTT) manufacturing pharmacy (UK). Labelling will be done entirely 
by GSTT. All of the relevant parties possess Home Office schedule 1 drugs licenses.   
 
 
10. Analysis 
The data collected from this study will be used to gather new information and inform future 
studies. Data will be tabulated and descriptive parameters derived. The study is powered for 
a baseline vs week 6 t-test on the QIDS-16 (condition 1 vs condition 2) and this is the primary 
efficacy outcome and endpoint.  
 
 
11. Dosing procedure and patient management  
It is strongly advised that psychedelic drugs only be taken in a positive environment where the 
patient feels comfortable and relaxed [70]. Efforts will be made to arrange the intervention 
room to promote relaxation without compromising medical safety. Mobile phones will be 
switched off during every session and efforts will be made to minimize unexpected 
interruptions.  
 
Patients will arrive in the morning at 9am but the dosing itself will take place at 10:30am. 
Patients will have been strongly advised to refrain from alcohol for a minimum of 24 hours 
prior to their arrival as alcohol may compound the effects of the drug and potentially interfere 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
38
with its effects. Patients will be psychologically prepared for the experience at screening. We 
will advise the patient to surrender to the experience and relaxing music will be used to 
facilitate calm and a relaxed, accepting mind-set. We will caution patients to expect some 
anxiety, and they will be encouraged to let us know if they feel this. Consistent with published 
guidelines on managing psychedelic-drug sessions, patients will be advised to accept feelings 
of anxiety and to allow the experience to unfold naturally, without psychological resistance 
[70].  
 
Based on our experience in the feasibility study, we will not initiate conversation with the 
patient. However, we will respond to them if they initiate contact. It is advised that active 
intervention is kept to a minimum during the acute experience. The patient is encouraged to 
explore their own mental space. Simple guided imagery may be used to assist relaxation.  
 
Sessions will take place in a purpose built clinical research facility with extensive nursing and 
emergency support, Invicro (previously called Imanova). All sessions will be supervised by at 
least 2 individuals. A study medical doctor will administer the drug/placebo and be available 
on site during the dosing sessions. If required, he/she can attend the therapy room within less 
than 5 minutes.  
 
After approximately 5 hours post dose, most of the acute subjective effects of psilocybin will 
have subsided and we will begin a thorough debriefing. This will involve encouraging the 
patient to give a detailed descriptive account of the experience. With the patient’s prior 
consent, dosing sessions will be video and/or audio recorded. Post-session interviews will also 
be video and audio recorded for qualitative analyses. At the end of the dosing day, a study 
medical doctor will assess the patient for potential discharge and the relevant capsules of 
escitalopram or placebo will be given, depending on the results of the randomisation.  
 
12. Randomisation 
Patients will be randomly allocated to one of the 2 conditions using a random sequence 
generator such as can be found online: 
(https://www.random.org/sequences/?min=1&max=66&col=3&format=html&rnd=new). 
The 
sequence can be initiated and managed by the dispensing pharmacist and schedule 1 license 
holder (Invicro, previously Imanova). Blinding and labelling will be done in collaboration with 
the manufacturing pharmacy (e.g. GSTT, Juniper and Fisher pharmaceuticals). An example 
of a random sequence for 2 conditions is provided below: 
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
39
Condition 1 
Condition 2 
2 
1 
3 
4 
5 
6 
8 
7 
10 
9 
12 
11 
13 
14 
15 
16 
18 
17 
19 
20 
22 
21 
24 
23 
25 
26 
27 
28 
30 
29 
32 
31 
34 
33 
35 
36 
38 
37 
40 
39 
41 
42 
43 
44 
46 
45 
48 
47 
50 
49 
51 
52 
54 
53 
56 
55 
57 
58 
60 
59 
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
40
Table 1. Example of a random sequence by which patients recruited to the trial enter the 
relevant conditions. This sequence is held by the dispensing pharmacy (at Invicro) who do not 
disclose the randomisation to the study team until situations where the blind is broken.  
 
Patient numbers will be independently monitored by InForm, the data system used by 
Imperial’s in house Clinical Trials Unit (Imp-CTU). Versions of objective tests will be 
counterbalanced using the same randomisation code (e.g. to ensure a 50:50 split, versions A 
and B will alternate, with version A provided first). Invicro will also direct the study team as to 
what version of tests will be used and they will also keep their own detailed log of which 
patients enter which condition. The Imp-CTU system uses InForm ITM (Integrated Trial 
Management) System, a web-based data entry system which builds an Oracle database for 
each individual clinical trial.   
 
13. Breaking of blind 
In the event of a medical emergency where breaking the blind is required to provide medical 
care to the trial participant, the investigator will have access to a mechanism that permits rapid 
unblinding should they feel this is necessary. The investigator will have the ability to unblind 
in an emergency without first discussing this with any other trial personnel or the sponsor. 
Thus, the blinding code for each participant will be kept in individual sealed, tamper-proof 
envelopes on site, for such scenarios. Treatment assignment should remain blinded unless 
that knowledge is necessary to determine subject emergency medical care. The rationale for 
unblinding must be clearly explained in source documentation and CRF, along with the date 
on which the treatment assignment was obtained. If there are no emergencies throughout the 
trial, unblinding will happen for all patients on Follow-Up 3, 6 weeks after the first psilocybin 
dosing session. For the purposes of the safety database maintained by Compass Pathways 
and Worldwide Clinical Trials (see section 7.5 above), they will be informed of the unblinding 
results at the end of the trial (after the last patient, last visit). 
 
 
 
14. Significant other assessment process 
We will also ask patients’ significant others for brief ratings of the patient's depression 
symptoms before and 6 weeks after the dosing day. The Significant Other Questionnaire has 
10 Likert scale items and will take approximately 10 minutes to complete. Patients and their 
significant other will be made aware that this is not a compulsory part of the study procedure.  
 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
41
The procedures for obtaining an assessment from a significant other will be as follows:  at 
screening, the patient will be asked if they consent to us contacting their significant other (a 
relevant item is included in the consent form). We will ask for the name and email address of 
a significant other. We will contact this person by email to explain that we are seeking ratings 
of depression symptoms for the patient in question. At the same time, they will be sent an 
information sheet and consent form to consider. If they choose to consent, they will return the 
completed consent form to us, after which, we will email them the pre-study questionnaire.  
We will explain that we will contact them via email at some point in the next six months to 
complete another rating. 
 
 
References 
[1] R.L. Carhart-Harris, M. Bolstridge, J. Rucker, C.M. Day, D. Erritzoe, M. Kaelen, 
M. Bloomfield, J.A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V.H. 
Curran, and D.J. Nutt, Psilocybin with psychological support for treatment-
resistant depression: an open-label feasibility study. Lancet Psychiatry (2016). 
[2] L. Osorio Fde, R.F. Sanches, L.R. Macedo, R.G. Santos, J.P. Maia-de-Oliveira, L. 
Wichert-Ana, D.B. Araujo, J. Riba, J.A. Crippa, and J.E. Hallak, 
Antidepressant effects of a single dose of ayahuasca in patients with recurrent 
depression: a preliminary report. Rev Bras Psiquiatr 37 (2015) 13-20. 
[3] C.S. Grob, A.L. Danforth, G.S. Chopra, M. Hagerty, C.R. McKay, A.L. 
Halberstadt, and G.R. Greer, Pilot study of psilocybin treatment for anxiety in 
patients with advanced-stage cancer. Arch Gen Psychiatry 68 (2011) 71-8. 
[4] M.J. R. Griffiths, M. Carducci, A. Umbricht, W. Richards, B. Richards, M. 
Cosimano and M. Klinedinst, Psilocybin produces substantial and sustained 
decreases in depression and anxiety in patients with life-threatening cancer: A 
randomized double-blind trial. Journal of psychopharmcology In press (2016). 
[5] A.B. S. Ross, J. Guss, G. Agin-Liebes, T. Malone, A. Belser, K. Kalliontzi, B. 
Cohen, J. Babb, Z. Su, P. Corby and B. Schmidt, Rapid and Sustained 
Symptom Reduction following psilocybin treatment for anxiety and depression 
in patients with life-threatening cancer: a randomized controlled trial. Journal 
of psychopharmcology In press (2016). 
[6] I.M. Cameron, J.R. Crawford, A.H. Cardy, S.W. du Toit, K. Lawton, S. Hay, K. 
Mitchell, S. Sharma, S. Shivaprasad, S. Winning, and I.C. Reid, Psychometric 
properties of the Quick Inventory of Depressive Symptomatology (QIDS-SR) 
in UK primary care. J Psychiatr Res 47 (2013) 592-8. 
[7] J.G. Storosum, B.J. van Zwieten, W. van den Brink, B.P. Gersons, and A.W. 
Broekmans, Suicide risk in placebo-controlled studies of major depression. 
The American journal of psychiatry 158 (2001) 1271-5. 
[8] K.R. Bonson, J.W. Buckholtz, and D.L. Murphy, Chronic administration of 
serotonergic antidepressants attenuates the subjective effects of LSD in 
humans. Neuropsychopharmacology 14 (1996) 425-36. 
[9] T.R. Mareth, and T.M. Brown, SSRI withdrawal. The Journal of clinical psychiatry 
57 (1996) 310. 
[10] N. Rao, The clinical pharmacokinetics of escitalopram. Clinical pharmacokinetics 
46 (2007) 281-90. 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
42
[11] K.L. Nugent, E. Spahr, J. Toroney, R. Mojtabai, C. Nettles, L.W. Turner, A. 
Fenton, A. Spivak, B.A. Cullen, A. Everett, and W.W. Eaton, Interrater 
reliability of the modified Monitoring of Side Effects Scale for assessment of 
adverse effects of psychiatric medication in clinical and research settings. 
Journal of clinical psychopharmacology 35 (2015) 324-8. 
[12] A.J. Rush, M.H. Trivedi, H.M. Ibrahim, T.J. Carmody, B. Arnow, D.N. Klein, J.C. 
Markowitz, P.T. Ninan, S. Kornstein, R. Manber, M.E. Thase, J.H. Kocsis, and 
M.B. Keller, The 16-Item Quick Inventory of Depressive Symptomatology 
(QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric 
evaluation in patients with chronic major depression. Biological psychiatry 54 
(2003) 573-83. 
[13] A.T. Beck, R.A. Steer, and M.G. Carbin, Psychometric properties of the Beck 
Depression Inventory: Twenty-five years of evaluation. Clinical psychology 
review 8 (1988) 77-100. 
[14] M. Hamilton, A rating scale for depression. Journal of Neurology, Neurosurgery 
& Psychiatry 23 (1960) 56-62. 
[15] C.D. Spielberger, Manual for the State-Trait Anxiety Inventory STAI (form Y)(" 
self-evaluation questionnaire").  (1983). 
[16] R. Tennant, L. Hiller, R. Fishwick, S. Platt, S. Joseph, S. Weich, J. Parkinson, J. 
Secker, and S. Stewart-Brown, The Warwick-Edinburgh mental well-being 
scale (WEMWBS): development and UK validation. Health and Quality of life 
Outcomes 5 (2007) 1. 
[17] R.P. Snaith, M. Hamilton, S. Morley, A. Humayan, D. Hargreaves, and P. 
Trigwell, A scale for the assessment of hedonic tone the Snaith-Hamilton 
Pleasure Scale. The British Journal of Psychiatry 167 (1995) 99-103. 
[18] H. Glaesmer, W. Rief, A. Martin, R. Mewes, E. Brähler, M. Zenger, and A. Hinz, 
Psychometric properties and population‐based norms of the Life Orientation 
Test Revised (LOT‐R). British journal of health psychology 17 (2012) 432-445. 
[19] M.F. Steger, T.B. Kashdan, B.A. Sullivan, and D. Lorentz, Understanding the 
search for meaning in life: Personality, cognitive style, and the dynamic 
between seeking and experiencing meaning. Journal of personality 76 (2008) 
199-228. 
[20] B.W. Smith, J. Dalen, K. Wiggins, E. Tooley, P. Christopher, and J. Bernard, 
The brief resilience scale: assessing the ability to bounce back. International 
journal of behavioral medicine 15 (2008) 194-200. 
[21] A.N. Weissman, The dysfunctional attitude scale: A validation study.  (1979). 
[22] O.P. John, E.M. Donahue, and R.L. Kentle, The big five inventory—versions 4a 
and 54, Berkeley, CA: University of California, Berkeley, Institute of 
Personality and Social Research, 1991. 
[23] E. Peters, S. Joseph, S. Day, and P. Garety, Measuring delusional ideation: the 
21-item Peters et al. Delusions Inventory (PDI). Schizophrenia bulletin 30 
(2004) 1005. 
[24] J. Parnas, P. Møller, T. Kircher, J. Thalbitzer, L. Jansson, P. Handest, and D. 
Zahavi, EASE: examination of anomalous self-experience. Psychopathology 
38 (2005) 236-258. 
[25] W. Treynor, R. Gonzalez, and S. Nolen-Hoeksema, Rumination reconsidered: A 
psychometric analysis. Cognitive therapy and research 27 (2003) 247-259. 
[26] D.M. Wegner, and S. Zanakos, Chronic thought suppression. Journal of 
personality 62 (1994) 615-640. 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
43
[27] J.H. Patton, and M.S. Stanford, Factor structure of the Barratt impulsiveness 
scale. Journal of clinical psychology 51 (1995) 768-774. 
[28] W. Gámez, M. Chmielewski, R. Kotov, C.Ruggero, N.Suzuki, and D. Watson, 
The Brief Experiencial Avoidance Questionnaire: Development and Initial 
Validation. Psychological Assessment 26 (2014) 35-45. 
 [29] A. Tellegen, and G. Atkinson, Openness to absorbing and self-altering 
experiences (" absorption"), a trait related to hypnotic susceptibility. Journal of 
abnormal psychology 83 (1974) 268. 
[30] R. Mcguire-Snieckus, R. McCABE, J. Catty, L. Hansson, and S. Priebe, A new 
scale to assess the therapeutic relationship in community mental health care: 
STAR. Psychological medicine 37 (2007) 85-95. 
[31] G.J. Devilly, and T.D. Borkovec, Psychometric properties of the 
credibility/expectancy questionnaire. Journal of behavior therapy and 
experimental psychiatry 31 (2000) 73-86. 
[32] E.K. Nisbet, J.M. Zelenski, and S.A. Murphy, The nature relatedness scale: 
Linking individuals' connection with nature to environmental concern and 
behavior. Environment and Behavior (2008). 
[33] R.M. Lee, and S.B. Robbins, Measuring belongingness: The Social 
Connectedness and the Social Assurance scales. Journal of Counseling 
Psychology 42 (1995) 232. 
[34] P.Bech, O.J. Rafaelsen, P. Kramp, T.G. Bolwig. The mania rating scale: scale 
construction and inter-observer agreement. Neuropharmacology (1978) 17 (6) 
430-431. 
 [35] J.Y. Hwang, T. Plante, and K. Lackey, The development of the Santa Clara 
brief compassion scale: An abbreviation of Sprecher and Fehr’s 
compassionate love scale. Pastoral Psychology 56 (2008) 421-428. 
[36] M.E. McCullough, R.A. Emmons, and J.-A. Tsang, The grateful disposition: a 
conceptual and empirical topography. Journal of personality and social 
psychology 82 (2002) 112. 
[37] R. Kotov, S.B. Bellman, and D.B. Watson, Multidimensional Iowa Suggestibility 
Scale (MISS) Brief Manual. Stoneybrook Medicine website (2004). 
[38] M. Rosenberg, Society and the adolescent self-image.  (1965). 
[39] R.L. Piedmont, Does spirituality represent the sixth factor of personality? 
Spiritual transcendence and the five‐factor model. Journal of personality 67 
(1999) 985-1013. 
[40] J. Price, V. Cole, H. Doll, and G.M. Goodwin, The Oxford Questionnaire on the 
Emotional Side-effects of Antidepressants (OQuESA): Development, validity, 
reliability and sensitivity to change. Journal of affective disorders 140 (2012) 
66-74. 
[41] A. Opbroek, P.L. Delgado, C. Laukes, C. McGahuey, J. Katsanis, F.A. Moreno, 
and R. Manber, Emotional blunting associated with SSRI-induced sexual 
dysfunction. Do SSRIs inhibit emotional responses? International Journal of 
Neuropsychopharmacology 5 (2002) 147-151. 
[42] E.A. Holmes, M.B. Bonsall, S.A. Hales, H. Mitchell, F. Renner, S.E. Blackwell, P. 
Watson, G.M. Goodwin, and M. Di Simplicio, Applications of time-series 
analysis to mood fluctuations in bipolar disorder to promote treatment 
innovation: a case series. Translational psychiatry 6 (2016) e720. 
[43] B. Platt, S. Kamboj, C.J.A. Morgan, and H.V. Curran, Processing dynamic facial 
affect in frequent cannabis-users: evidence of deficits in the speed of 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
44
identifying emotional expressions. Drug and alcohol dependence 112 (2010) 
27-32. 
[44] J.M. Williams, and K. Broadbent, Autobiographical memory in suicide 
attempters. Journal of abnormal psychology 95 (1986) 144. 
[45] D.R. Strunk, H. Lopez, and R.J. DeRubeis, Depressive symptoms are 
associated with unrealistic negative predictions of future life events. Behaviour 
research and therapy 44 (2006) 861-882. 
[46] E.P. Torrance, Torrance tests of creative thinking, Personnel Press, 
Incorporated, 1968. 
[47] M.M. Nour, L. Evans, D. Nutt, and R.L. Carhart-Harris, Ego-Dissolution and 
Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in 
human neuroscience 10 (2016) 269. 
[48] F.S. Barrett, M.W. Johnson, and R.R. Griffiths, Validation of the revised Mystical 
Experience Questionnaire in experimental sessions with psilocybin. Journal of 
psychopharmacology 29 (2015) 1182-90. 
[49] E. Studerus, A. Gamma, and F.X. Vollenweider, Psychometric evaluation of the 
altered states of consciousness rating scale (OAV). PloS one 5 (2010) 
e12412. 
[50] O.J. Mason, C.J. Morgan, A. Stefanovic, and H.V. Curran, The psychotomimetic 
states inventory (PSI): measuring psychotic-type experiences from ketamine 
and cannabis. Schizophr Res 103 (2008) 138-42. 
[51] M. Zentner, D. Grandjean, and K.R. Scherer, Emotions evoked by the sound of 
music: characterization, classification, and measurement. Emotion 8 (2008) 
494. 
[52] F.S. Barrett, M.P. Bradstreet, J.-M.S. Leoutsakos, M.W. Johnson, and R.R. 
Griffiths, The Challenging Experience Questionnaire: Characterization of 
challenging experiences with psilocybin mushrooms. Journal of 
Psychopharmacology (2016). 
[53] B. Greyson, The Near-Death Experience Scale: Construction, Reliability, and 
Validity. The Journal of nervous and mental disease 171 (1983) 369-375. 
[54] T. Passie, J. Seifert, U. Schneider, and H.M. Emrich, The pharmacology of 
psilocybin. Addict Biol 7 (2002) 357-64. 
[55] R.R. Griffiths, M.W. Johnson, W.A. Richards, B.D. Richards, U. McCann, and R. 
Jesse, Psilocybin occasioned mystical-type experiences: immediate and 
persisting dose-related effects. Psychopharmacology 218 (2011) 649-65. 
[56] R.R. Griffiths, W.A. Richards, U. McCann, and R. Jesse, Psilocybin can 
occasion mystical-type experiences having substantial and sustained 
personal meaning and spiritual significance. Psychopharmacology 187 (2006) 
268-83; discussion 284-92. 
[57] E. Studerus, M. Kometer, F. Hasler, and F.X. Vollenweider, Acute, subacute and 
long-term subjective effects of psilocybin in healthy humans: a pooled 
analysis of experimental studies. J Psychopharmacol 25 (2011) 1434-52. 
[58] M.P. Bogenschutz, and M.W. Johnson, Classic hallucinogens in the treatment of 
addictions. Prog Neuropsychopharmacol Biol Psychiatry 64 (2016) 250-8. 
[59] T.S. Krebs, and P.O. Johansen, Lysergic acid diethylamide (LSD) for 
alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 
26 (2012) 994-1002. 
[60] F.A. Moreno, C.B. Wiegand, E.K. Taitano, and P.L. Delgado, Safety, tolerability, 
and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. 
The Journal of clinical psychiatry 67 (2006) 1735-40. 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
45
[61] R. Griffiths, W. Richards, M. Johnson, U. McCann, and R. Jesse, Mystical-type 
experiences occasioned by psilocybin mediate the attribution of personal 
meaning and spiritual significance 14 months later. J Psychopharmacol 22 
(2008) 621-32. 
[62] R.L. Carhart-Harris, T.M. Williams, B. Sessa, R.J. Tyacke, A.S. Rich, A. 
Feilding, and D.J. Nutt, The administration of psilocybin to healthy, 
hallucinogen-experienced volunteers in a mock-functional magnetic 
resonance imaging environment: a preliminary investigation of tolerability. J 
Psychopharmacol 25 (2011) 1562-7. 
[63] R.L. Carhart-Harris, D. Erritzoe, T. Williams, J.M. Stone, L.J. Reed, A. Colasanti, 
R.J. Tyacke, R. Leech, A.L. Malizia, K. Murphy, P. Hobden, J. Evans, A. 
Feilding, R.G. Wise, and D.J. Nutt, Neural correlates of the psychedelic state 
as determined by fMRI studies with psilocybin. Proceedings of the National 
Academy of Sciences of the United States of America 109 (2012) 2138-43. 
[64] S.D. Muthukumaraswamy, R.L. Carhart-Harris, R.J. Moran, M.J. Brookes, T.M. 
Williams, D. Errtizoe, B. Sessa, A. Papadopoulos, M. Bolstridge, K.D. Singh, 
A. Feilding, K.J. Friston, and D.J. Nutt, Broadband Cortical Desynchronization 
Underlies the Human Psychedelic State. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 33 (2013) 15171-15183. 
[65] R.L. Carhart-Harris, M. Bolstridge, J. Rucker, C.M. Day, D. Erritzoe, M. Kaelen, 
M. Bloomfield, J.A. Rickard, B. Forbes, A. Feilding, D. Taylor, S. Pilling, V.H. 
Curran, and D.J. Nutt, Psilocybin with psychological support for treatment-
resistant depression: an open-label feasibility study. Lancet Psychiatry 3 
(2016) 619-27. 
[66] R.R. Griffiths, M.W. Johnson, M.A. Carducci, A. Umbricht, W.A. Richards, B.D. 
Richards, M.P. Cosimano, and M.A. Klinedinst, Psilocybin produces 
substantial and sustained decreases in depression and anxiety in patients 
with life-threatening cancer: A randomized double-blind trial. Journal of 
psychopharmacology (Oxford, England) 30 (2016) 1181. 
[67] E. Maron, M. Wall, R. Norbury, B. Godlewska, S. Terbeck, P. Cowen, P. 
Matthews, and D.J. Nutt, Effect of short-term escitalopram treatment on 
neural activation during emotional processing. J Psychopharmacol 30 (2016) 
33-9. 
[68] R.L. Carhart-Harris, and D.J. Nutt, Experienced drug users assess the relative 
harms and benefits of drugs: a web-based survey. Journal of psychoactive 
drugs 45 (2013) 322-8. 
[69] T.M. Carbonaro, M.P. Bradstreet, F.S. Barrett, K.A. MacLean, R. Jesse, M.W. 
Johnson, and R.R. Griffiths, Survey study of challenging experiences after 
ingesting psilocybin mushrooms: Acute and enduring positive and negative 
consequences. J Psychopharmacol (2016). 
[70] M.W. Johnson, W.A. Richards, and R.R. Griffiths, Human hallucinogen 
research: guidelines for safety. Journal of Psychopharmacology (2008). 
[71] A. Cipriani, X. Zhou, C. Del Giovane, S.E. Hetrick, B. Qin, C. Whittington, D. 
Coghill, Y. Zhang, P. Hazell, and S. Leucht, Comparative efficacy and 
tolerability of antidepressants for major depressive disorder in children and 
adolescents: a network meta-analysis. The Lancet (2016). 
[72] P.S. Hendricks, C.B. Thorne, C.B. Clark, D.W. Coombs, and M.W. Johnson, 
Classic psychedelic use is associated with reduced psychological distress and 
suicidality in the United States adult population. J Psychopharmacol (2015). 
[73] D. Fergusson, S. Doucette, K.C. Glass, S. Shapiro, D. Healy, P. Hebert, and B. 
Hutton, Association between suicide attempts and selective serotonin 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
46
reuptake inhibitors: systematic review of randomised controlled trials. BMJ 
330 (2005) 396. 
[74] T.A. Hammad, T.P. Laughren, and J.A. Racoosin, Suicide rates in short-term 
randomized controlled trials of newer antidepressants. J Clin 
Psychopharmacol 26 (2006) 203-7. 
[75] T. Sharma, L.S. Guski, N. Freund, and P.C. Gotzsche, Suicidality and 
aggression during antidepressant treatment: systematic review and meta-
analyses based on clinical study reports. BMJ 352 (2016) i65. 
[76] J.G. Storosum, B.J. van Zwieten, W. van den Brink, B.P. Gersons, and A.W. 
Broekmans, Suicide risk in placebo-controlled studies of major depression. 
The American journal of psychiatry 158 (2001) 1271-5. 
[77] A. Cipriani et al. Comparative efficacy and acceptability of 12 new-generation 
antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 
373(9665):746-58 
[78] C. Bræstrup, C. Sanchez. Escitalopram: a unique mechanism of action. Int J 
Psychiatry Clin Pract. (2004) Suppl 1:11-3.  
[79]  http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-22-tab11C-
Lexapro-Tabs-SLR015.pdf  
[80] Y. D. Hu et al. Single i.v. ketamine augmentation of newly initiated escitalopram 
for major depression: results from a randomized, placebo-controlled 4-week 
study. Psychol Med (2016) 46(3) 
[81]  V. Lalit et al. Escitalopram Versus Citalopram and Sertraline: A Double-Blind 
Controlled, Multi-centric Trial in Indian Patients with Unipolar Major 
Depression. Indian J Psychiatry (2004) 46(4):333-41. 
[82] W.R.  Lenderking, Hu M, Cappelleri JC, Rush AJ. Reliability, validity, and 
responsiveness of the QIDS-SR16 daily version. International Society of 
Quality of Life Research. (2005) Annual Meeting, San Francisco, CA. 
[83] A.L.  Montejo, Rico-Villademoros F. Psychometric properties of the 
Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-
SALSEX) in patients with schizophrenia and other psychotic disorders. J Sex 
Marital Ther. (2008) 34(3):227-39. 
[84] Van Spijker, B.A.J., Batterham, P.J., Calear, A.L., Farrer, L., Christensen, H., Reynolds, 
J. & Kerkhof, A.J.F.M. (2014). The Suicidal Ideation Attributes Scale (SIDAS): 
Community-based validation study of a new scale for the measurement of suicidal 
ideation. Suicide and Life-Threatening Behavior, 44 (4), 408-419.  
[85]  T.R. Barnes. A rating scale for drug-induced akathisia. 
Br J Psychiatry (1989) 154:672-6. 
[86] 
https://www.evidence.nhs.uk/formulary/bnf/current/a1-interactions/list-of-drug-
interactions/antidepressants 
[87]     http://www.rxlist.com/drug-interactions/serious-index/escitalopram-oral.htm 
[88]     Cooper, C.M., Whiting, D.A., Cowen, P.J., Harmer, C.J. Tianeptine in an 
experimental medicine model of antidepressant action. Journal of 
Psychopharmacology (2015) 29 (5) 582-590. 
[89] Kaelen, M., Barrett, F.S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., 
Curran, H.V., Feilding, A., Nutt, D.J., Carhart-Harris, R. L. LSD enhances emotional 
response to music. Journal of Psychopharmacology (2015) 232 (19) 3607-3614 
[90] Delis, D.C., Kramer, J.H., Kaplan, E., Ober, B.A. California Verbal Learning 
Test: Adult version. Manual. (1987) Psychological Corporation, San Antonio, TX 
[91] Jaeger, J. and Domingo S.Z. The Digit Symbol Substitution Test (DSST): 
psychometric properties and clinical utility in major depressive disorder. Poster 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
47
presented at the 29th ECNP Congress, 17-20 September, 2016, Vienna, Austria. 
https://www.ecnp.eu/presentationpdfs/57/P.1.j.033.pdf  
[92] Arias, B., Gastó, C., Catalán, R., Gutiérrez, B., Pintor, L., & Fañanás, L. (2001). 
The 5‐HT2A receptor gene 102T/C polymorphism is associated with suicidal behavior 
in depressed patients. American Journal of Medical Genetics, 105(8), 801–804. 
http://doi.org/10.1002/ajmg.10099 
[93] Group, E. M. A. S. O. S. E., Williams, J., Spurlock, G., McGuffin, P., Owen, M. J., 
Mallet, J., et al. (1996). Association between schizophrenia and T102C polymorphism 
of the 5-hydroxytryptamine type 2a-receptor gene. The Lancet, 347(9011), 1294–
1296. http://doi.org/10.1016/S0140-6736(96)90939-3 
[94] Data Protection Act: http://www.legislation.gov.uk/ukpga/1998/29/contents  
[95] Evans, Lisa & Nutt, David & Carhart-Harris, Robin. (2016). Ego-Dissolution and 
Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human 
Neuroscience. 10. . 10.3389/fnhum.2016.00269. 
[96] P.Moran, M.Leese, T. Lee, P.Walters, G. Thornicroft, A. Mann, Standard 
Assessment of Personality – Abbreviated Scale (SAPAS): preliminary validation of a 
brief screen for personality disorder. The British Journal of Psychiatry (2003). 183 (3) 
228-232. 
[97] S.R. Kay, A. Fiszbein, L.A.Opler. The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophrenia Bulletin (1987) 13 (2) 261-76 
[98] Brunoni, A.R., Moffa, A.H., Sampaio-Junior, B., Borrione, L., Moreino, M.L., 
Fernandes, R.A., Veronezi, B.P., Nogueira, B.S. Aparicio, L.V.M., Razza, L.B., 
Chamorro, R., Tort, L.C., Fraguas, R., Lotufo, P.A., Gattaz, W.F., Fregni, F., 
Bendenor, I.M. Trial of Electrical Direct-Current Therapy versus Escitalopram for 
Depression. The New England Journal of Medicine (2017) 376, 2523-33. DOI: 
10.1056/NEJMoa1612999  
[99] Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: 
mechanisms and clinical management. Therapeutic Advances in Drug Safety. 
2012;3(5):241-253. doi:10.1177/2042098612454283. 
[100] Medicines and Healthcare products Regulatory Agency report on Escitalopram, 
20mg film coated capsules SmPC document (spc-doc_PL 00289-1727.pdf) found on 
http://www.mhra.gov.uk/spc-pil/?prodName=ESCITALOPRAM  20 MG FILM-
COATED TABLETS&subsName=ESCITALOPRAM 
OXALATE&pageID=SecondLevel (Accessed 12/03/2018, 16:00). 
[101] http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
[102] Diener, Ed & Wirtz, Derrick & Biswas-Diener, Robert & Tov, William & Kim-
Prieto, Chu & Choi, Dong-won & Oishi, Shigehiro. (2009). New Measures of Well-
Being. Social Indicators Research Series. 39. 247-266. 10.1007/978-90-481-2354-
4_12. 
[103] Kolden GG, Strauman TJ, Gittleman M, Halverson JL, Heerey E, Schneider KL. 
The Therapeutic Realizations Scale-Revised (TRS-R): psychometric characteristics 
and relationship to treatment process and outcome. Journal of Clinical Psychology. 
2000;56(9):1207–1220. 
[104] Taylor JF, Rosen RC, Leiblum SR. Self-Report Assessment of Female Sexual 
Function: Psychometrie Evaluation of the Brief Index of Sexual Functioning for 
Women. Archives of Sexual Behaviour. 1994:23 (6) 627- 643. 
[105] Felitti VC, Anda RF, Nordenberg D, Williamson DF, Spitz AM, Edwards V, Koss 
MP, Marks JS. Relationship of Child Abuse and Household Dysfunction to Many of 

 
 
 
PSILODEP RCT – Study Protocol, Version 7, 11/07/2019 
48
the Leading Causes of Death in Adults – The Adverse Childhoood Experiences (ACE) 
Study. American Journal of Preventive Medicine. 1998:14(4) 245-355. 
[106] Grant AM, Frankling J, Langford P. The Self-reflection and Insight Scale: A New 
Measure of Private Self-Consciousness. Social Behaviour and Personality. 2002: 
30(8), 821-836. 
[107] Bond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. 
K., Waltz, T., & Zettle, R. D. (in press). Preliminary psychometric properties of the 
Acceptance and Action Questionnaire – II: A revised measure of psychological 
inflexibility and experiential avoidance. Behavior Therapy. 
[108] Francis A. W., Dawson, D. L., & Golijani-Moghaddam, N. (2016). The 
development and validation of the Comprehensive assessment of Acceptance and 
Commitment Therapy processes (CompACT). Journal of Contextual Behavioral 
Science, 5(3), 134-145.